View Filing Data

Operating Leases

Finance Leases

Weighted-average remaining lease term (years)

Weighted-average discount rate

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Nov. 05, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	NN INC
Entity Central Index Key	0000918541
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus (i.e. Q1,Q2,Q3,FY)	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		42,327,206
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Net sales	$ 213,897,000	$ 205,683,000	$ 648,819,000	$ 571,180,000
Cost of sales (exclusive of depreciation and amortization shown separately below)	160,816,000	156,408,000	485,598,000	431,492,000
Selling, general and administrative expense	24,043,000	22,480,000	78,911,000	71,298,000
Acquisition related costs excluded from selling, general and administrative expense	0	597,000	0	5,810,000
Depreciation and amortization	22,621,000	21,259,000	68,970,000	51,798,000
Restructuring and integration expense, net	0	(209,000)	(12,000)	2,137,000
Other operating (income) expense, net	(1,255,000)	(733,000)	(1,019,000)	(638,000)
Income from operations	7,672,000	5,881,000	16,371,000	9,283,000
Interest expense	14,733,000	18,608,000	42,492,000	46,592,000
Loss on extinguishment of debt and write-off of debt issuance costs	0	6,624,000	2,699,000	19,562,000
Other (income) expense, net	98,000	308,000	884,000	1,882,000
Loss before (provision) benefit for income taxes and share of net income from joint venture	(7,159,000)	(19,659,000)	(29,704,000)	(58,753,000)
Benefit (provision) for income taxes	1,283,000	5,609,000	(1,535,000)	12,213,000
Share of net income from joint venture	279,000	266,000	345,000	1,744,000
Net loss	(5,597,000)	(13,784,000)	(30,894,000)	(44,796,000)
Other comprehensive loss:
Foreign currency translation adjustment	(11,448,000)	(4,193,000)	(11,620,000)	(14,509,000)
Change in fair value of interest rate swap, net of tax	(1,181,000)		(11,999,000)
Change in fair value of interest rate swap, net of tax		0		0
Less: reclassification adjustment for (gains) losses included in net income, net of tax	238,000	0	238,000	0
Other comprehensive loss	(12,391,000)	(4,193,000)	(23,381,000)	(14,509,000)
Comprehensive loss	$ (17,988,000)	$ (17,977,000)	$ (54,275,000)	$ (59,305,000)
Basic net loss per share:
Net loss per share (in dollars per shares)	$ (0.13)	$ (0.48)	$ (0.74)	$ (1.61)
Weighted average shares outstanding (in shares)	42,038	28,688	42,013	27,784
Diluted net loss per share:
Net loss per share (in dollars per share)	$ (0.13)	$ (0.48)	$ (0.74)	$ (1.61)
Weighted average shares outstanding (in shares)	42,038	28,688	42,013	27,784

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 24,409	$ 17,988
Accounts receivable, net	141,583	133,421
Inventories	126,832	122,615
Income tax receivable	1,610	2,277
Other current assets	21,884	21,901
Total current assets	316,318	298,202
Property, plant and equipment, net	364,479	361,028
Operating lease right-of-use assets	67,885	0
Goodwill	437,280	439,452
Intangible assets, net	340,513	376,248
Investment in joint venture	19,877	20,364
Other non-current assets	7,393	7,607
Total assets	1,553,745	1,502,901
Current liabilities:
Accounts payable	65,534	65,694
Accrued salaries, wages and benefits	31,919	24,636
Accrued Income Taxes, Current	1,360	0
Current maturities of long-term debt	25,601	31,280
Current portion of operating lease liabilities	7,047	0
Other current liabilities	24,548	23,420
Total current liabilities	156,009	145,030
Deferred tax liabilities	77,182	91,838
Non-current income tax payable	3,569	3,875
Long-term debt, net of current portion	841,748	811,471
Operating lease liabilities, net of current portion	68,479	0
Other non-current liabilities	46,961	29,417
Total liabilities	1,193,948	1,081,631
Commitments and contingencies (Note 12)
Common stock - $0.01 par value per share, authorized 90,000 shares, 42,297 and 42,104 shares issued and outstanding at September 30, 2019, and December 31, 2018, respectively	423	421
Additional paid-in capital	513,268	511,545
Retained deficit	(98,888)	(59,071)
Accumulated other comprehensive loss	(55,006)	(31,625)
Total stockholders’ equity	359,797	421,270
Total liabilities and stockholders’ equity	$ 1,553,745	$ 1,502,901

Condensed Consolidated Balance Sheets - Parenthetical - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	90,000,000	45,000,000
Common stock, shares issued (in shares)	42,297,000	42,104,000
Common stock, shares outstanding (in shares)	42,297,000	42,104,000

Condensed Consolidated Statement of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	AOCI Attributable to Parent
Beginning balance (in shares) at Dec. 31, 2017		27,572,000
Beginning balance at Dec. 31, 2017	$ 486,104	$ 275	$ 292,494	$ 211,080	$ (17,745)
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Net loss	(44,796)			(44,796)
Cash dividends declared	$ (5,836)			(5,836)
Stock Issued During Period, Shares, New Issues	14,375,000
Stock Issued During Period, Value, New Issues	$ 217,312	$ 144	217,168
Share-based compensation expense (in shares)		(165,000)
Share-based compensation expense	3,425	$ 2	3,423
Shares issued for option exercises (in shares)		27,000
Shares issued for option exercises	274		274
Restricted shares and performance shares forgiven for taxes and forfeited (in shares)		(35,000)
Restricted shares and performance shares forgiven for taxes and forfeited	(723)		(723)
Adjustments to Additional Paid in Capital, Adjustments to Performance Shares Vesting Estimates	(753)		(802)	49
Reclassification of interest rate swap settlement to income, net of tax of $68	0
Foreign currency translation loss	(14,509)				(14,509)
Ending balance (in shares) at Sep. 30, 2018		42,104,000
Ending balance at Sep. 30, 2018	640,515	$ 421	511,834	160,514	(32,254)
Beginning balance (in shares) at Jun. 30, 2018		27,729,000
Beginning balance at Jun. 30, 2018	442,795	$ 277	294,380	176,199	(28,061)
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Net loss	(13,784)			(13,784)
Cash dividends declared	$ (1,950)			(1,950)
Stock Issued During Period, Shares, New Issues	14,375,000
Stock Issued During Period, Value, New Issues	$ 217,312	$ 144	217,168
Share-based compensation expense	1,091		1,091
Restricted shares and performance shares forgiven for taxes and forfeited	(3)		(3)
Adjustments to Additional Paid in Capital, Adjustments to Performance Shares Vesting Estimates	753		802	(49)
Reclassification of interest rate swap settlement to income, net of tax of $68	0
Foreign currency translation loss	(4,193)				(4,193)
Ending balance (in shares) at Sep. 30, 2018		42,104,000
Ending balance at Sep. 30, 2018	640,515	$ 421	511,834	160,514	(32,254)
Beginning balance (in shares) at Dec. 31, 2018		42,104,000
Beginning balance at Dec. 31, 2018	421,270	$ 421	511,545	(59,071)	(31,625)
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Net loss	(30,894)			(30,894)
Cash dividends declared	(8,907)			(8,907)
Share-based compensation expense (in shares)		(231,000)
Share-based compensation expense	$ 3,130	$ 2	3,128
Shares issued for option exercises (in shares)	5,000	5,000
Shares issued for option exercises	$ 21		21
Restricted shares and performance shares forgiven for taxes and forfeited (in shares)		(43,000)
Restricted shares and performance shares forgiven for taxes and forfeited	(151)		(151)
Adjustments to Additional Paid in Capital, Adjustments to Performance Shares Vesting Estimates	(1,240)		(1,275)	35
Change in fair value of interest rate swap, net of tax of $376	(11,999)				(11,999)
Reclassification of interest rate swap settlement to income, net of tax of $68	238				238
Foreign currency translation loss	(11,620)				(11,620)
Ending balance (in shares) at Sep. 30, 2019		42,297,000
Ending balance at Sep. 30, 2019	359,797	$ 423	513,268	(98,888)	(55,006)
Beginning balance (in shares) at Jun. 30, 2019		42,367,000
Beginning balance at Jun. 30, 2019	380,836	$ 424	513,380	(90,353)	(42,615)
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Net loss	(5,597)			(5,597)
Cash dividends declared	(2,973)			(2,973)
Share-based compensation expense	1,151		1,152
Shares issued for option exercises (in shares)		5,000
Shares issued for option exercises	21		21
Restricted shares and performance shares forgiven for taxes and forfeited (in shares)		(25,000)
Restricted shares and performance shares forgiven for taxes and forfeited	(10)		(10)
Adjustments to Additional Paid in Capital, Adjustments to Performance Shares Vesting Estimates	(1,240)		(1,275)	35
Change in fair value of interest rate swap, net of tax of $376	(1,181)				(1,181)
Reclassification of interest rate swap settlement to income, net of tax of $68	238				238
Foreign currency translation loss	(11,448)				(11,448)
Ending balance (in shares) at Sep. 30, 2019		42,297,000
Ending balance at Sep. 30, 2019	$ 359,797	$ 423	$ 513,268	$ (98,888)	$ (55,006)

Condensed Consolidated Statement of Changes in Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Statement of Stockholders' Equity [Abstract]
Change in fair value interest rate swap, tax	$ 376	$ 3,472
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax	$ 68	$ 68

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities
Net loss	$ (30,894)	$ (44,796)
Adjustments to reconcile net loss to net cash provided by (used by) operating activities:
Depreciation and amortization	68,970	51,798
Amortization of debt issuance costs	3,538	3,631
Loss on extinguishment of debt and write-off of debt issuance costs	2,699	19,562
Share of net income from joint venture, net of cash dividends received	(345)	(1,744)
Compensation expense from issuance of share-based awards	1,855	2,623
Deferred income taxes	(11,024)	(14,737)
Other	2,091	255
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(9,929)	(19,656)
Inventories	(5,794)	(18,207)
Accounts payable	(334)	3,733
Income taxes receivable and payable, net	1,696	(1,681)
Other	11,078	6,004
Net cash provided by (used in) operating activities	33,607	(13,215)
Cash flows from investing activities
Acquisition of property, plant and equipment	(40,720)	(46,998)
Proceeds from liquidation of short-term investment	8,000	0
Cash paid to acquire businesses, net of cash received	0	(399,011)
Other	1,723	650
Net cash used in investing activities	(30,997)	(445,359)
Cash flows from financing activities
Cash paid for debt issuance or prepayment costs	(1,016)	(20,703)
Dividends paid	(8,879)	(5,812)
Proceeds from Issuance of Common Stock	0	217,435
Proceeds from long-term debt	52,144	288,594
Repayment of long-term debt	(26,634)	(234,000)
Proceeds from (repayments of) short-term debt, net	(6,086)	10,474
Other	(2,636)	(3,161)
Net cash provided by financing activities	6,893	252,827
Effect of exchange rate changes on cash flows	(3,082)	(910)
Net change in cash and cash equivalents	6,421	(206,657)
Cash and cash equivalents at beginning of period	17,988	224,446
Cash and cash equivalents at end of period	$ 24,409	$ 17,789

Interim Financial Statements	9 Months Ended
Interim Financial Statements	Sep. 30, 2019
Quarterly Financial Information Disclosure [Abstract]
Interim Financial Statements	Interim Financial Statements Nature of Business NN, Inc. is a global diversified industrial company that combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for the medical, aerospace and defense, electrical, automotive, and general industrial markets. As used in this Quarterly Report on Form 10-Q (this “Quarterly Report), the terms “NN,” the “Company,” “we,” “our,” or “us” refer to NN, Inc., and its subsidiaries. Basis of Presentation In accordance with Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date of the issuance of these unaudited interim financial statements. The Company’s existing revolving line of credit, which has a maximum capacity of $110.0 million, matures on October 19, 2020 (the “Senior Secured Revolver”). The Company leverages such line of credit, along with cash generated from operations, to fund operations and working capital and had $71.5 million of outstanding borrowings as of November 6, 2019. Based on our current and projected use of the facility, as well as cash flows to be generated from operations and investing activities, we do not anticipate that we will be able to repay the outstanding borrowings when they become due in October 2020 without refinancing the line of credit or obtaining new financing. The Company has and continues to make efforts to obtain new financing; however, there is no assurance that we will obtain sufficient financing on commercially reasonable terms, if at all, before the outstanding amounts would be required to be repaid. This condition raises substantial doubt about the Company’s ability to continue as a going concern within one year after the date of issuance of these financial statements. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. The accompanying condensed consolidated financial statements have not been audited, except that the Condensed Consolidated Balance Sheet as of December 31, 2018, was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018 (the “2018 Annual Report”), which we filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 18, 2019. In management’s opinion, the accompanying unaudited condensed consolidated financial statements reflect all adjustments necessary to fairly state our results of operations for the three and nine months ended September 30, 2019 and 2018; financial position as of September 30, 2019, and December 31, 2018; and cash flows for the nine months ended September 30, 2019 and 2018, on a basis consistent with our audited consolidated financial statements other than the adoption of new accounting standards, such as the new lease standard (see Note 10). These adjustments are of a normal recurring nature and are, in the opinion of management, necessary to state fairly the Company’s financial position and operating results for the interim periods. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted from the interim financial statements presented in this Quarterly Report. These unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and accompanying notes included in the 2018 Annual Report. The results for the three and nine months ended September 30, 2019, are not necessarily indicative of results for the year ending December 31, 2019, or any other future periods. Except for per share data or as otherwise indicated, all U.S. dollar amounts presented in the tables in these Notes to Condensed Consolidated Financial Statements are in thousands. Prior Periods’ Financial Statement Revisions In connection with the preparation of our interim financial statements for the nine months ended September 30, 2019, we identified tax accounting misstatements in our previously issued 2018 Annual Report. Such misstatements relate to the tax accounting associated with the 2018 impairment of our joint venture as well as other immaterial tax misstatements. We assessed the materiality of the misstatements on prior periods’ financial statements in accordance with SEC Staff Accounting Bulletin (“SAB”) Topic 1.M, Materiality, codified in Accounting Standards Codification (“ASC”) Topic 250, Accounting Changes and Error Corrections, (“ASC 250”) and concluded that the misstatements were not material to the prior annual or interim periods. However, the Company has determined that it will revise its previously issued 2018 and 2017 annual financial statements, and relevant interim periods, to correct for these misstatements. In connection with such revision, the Company will correct for an immaterial tax misstatement that originated in 2017 and had been previously corrected for as an out of period adjustment in 2018. In connection with the filing of this Quarterly Report, we have revised the accompanying Consolidated Statements of Operations and Comprehensive Income (Loss) and our Consolidated Statements of Cash Flows for the nine months ended September 30, 2018, and have reflected the impact of the revision on our Consolidated Balance Sheet as of December 31, 2018. Refer to Note 17 for the effect of the correction of the misstatements on each of the financial statements noted above. Accounting Standards Recently Adopted Leases. On January 1, 2019, we adopted Accounting Standards Codification (“ASC”) 842, Leases, which superseded ASC 840, Leases. We adopted ASC 842 utilizing the modified retrospective transition approach; therefore, historical financial information and disclosures do not reflect the new standard and will continue to be presented under the previous lease accounting guidance. Under the modified retrospective transition method, the cumulative effect of the initial adoption adjustment of less than $0.1 million was recognized to the opening balance of retained deficit as of January 1, 2019. As part of the adoption, we elected the package of practical expedients, the short-term lease exemption, and the practical expedient to not separate lease and non-lease components. We recorded lease-related assets and liabilities to our balance sheet for leases with terms greater than twelve months that were classified as operating leases and not previously recorded on our balance sheet. See Note 10 for the required disclosures related to ASC 842. Derivatives and Hedging. In August 2017, the Financial Accounting Standards Board (“FASB”) issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, (“ASU 2017-12”). ASU 2017-12 provides new rules that expand the hedging strategies that qualify for hedge accounting. The new rules also allow additional time to complete hedge effectiveness testing and allow qualitative assessments subsequent to initial quantitative tests if there is a supportable expectation that the hedge will remain highly effective. We adopted the guidance on January 1, 2019. We have applied the new rules to 2019 hedging activities as disclosed in Note 16 to these condensed consolidated financial statements. The new guidance has no effect on our historical financial statements. Effects of Tax Reform in Other Comprehensive Income. In February 2018, the FASB issued guidance related to the impacts of the U.S. Tax Cuts and Jobs Act of 2017 (“Tax Act”). Under existing U.S. GAAP, the effects of changes in tax rates and laws on deferred tax balances are recorded as a component of income tax expense in the period in which the law was enacted. When deferred tax balances related to items originally recorded in accumulated other comprehensive income (“AOCI”) are adjusted, certain tax effects become stranded in AOCI. The FASB issued ASU 2018-2, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, that permits reclassification of certain income tax effects of the Tax Act from AOCI to retained earnings. The guidance also requires certain disclosures about stranded tax effects. The new guidance was effective for us on January 1, 2019. We adopted the new guidance at the beginning of the period of adoption. The new guidance had no effect on our financial statements. Accounting Standards Not Yet Adopted Fair Value Disclosures. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), that modifies fair value disclosure requirements. The new guidance could impact us by streamlining disclosures of Level 3 fair value measurements. The modified disclosures are effective for us beginning in the first quarter of 2020, with early adoption allowed. ASU 2018-13 changes disclosures only and does not impact our financial condition, results of operations, or cash flows. We are in the process of evaluating the effects of this guidance on our fair value disclosures. Internal-Use Software. In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force) (“ASU 2018-15”), that provides guidance on a customer’s accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by the vendor. Under the new guidance, customers will apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. ASU 2018-15 is effective for us on January 1, 2020, using either a prospective or retrospective approach and with early adoption permitted. We are in the process of evaluating the effects of this guidance on our financial statements, but do not expect the adoption to have a material impact. Financial Instruments - Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which modifies the measurement of expected credit losses on certain financial instruments and the timing of when such losses are recorded. ASU 2016-13 is effective for us on January 1, 2020, using a modified retrospective approach, with early adoption permitted. We are in the process of evaluating the effects of this guidance on our financial statements, but do not expect the adoption to have a material impact.

Acquisitions

9 Months Ended

Sep. 30, 2019

Business Combinations [Abstract]

Acquisitions

Paragon Medical, Inc.

On May 7, 2018, we acquired 100% of the stock of PMG Intermediate Holding Corporation, the parent company of Paragon Medical, Inc. (“Paragon Medical”). For accounting purposes, Paragon Medical meets the definition of a business and has been accounted for as a business combination. Paragon Medical is a medical device manufacturer that focuses on the orthopedic, case and tray, implant, and instrument markets. This acquisition continues our strategic focus to expand our Life Sciences portfolio as well as create a balanced business by diversifying our products and finished device offerings. We have finalized the purchase price allocation and recorded measurement period adjustments to the initial allocation as disclosed in our 2018 Annual Report.

Beginning May 7, 2018, our consolidated results of operations include the results of Paragon Medical.

The unaudited pro forma financial results shown in the table below for the three and nine months ended September 30, 2018, combine the consolidated results of NN and Paragon Medical giving effect to the Paragon Medical acquisition as if it had been completed on January 1, 2017. The unaudited pro forma financial results do not give effect to any of our other acquisitions that occurred after January 1, 2017, and do not include any anticipated synergies or other assumed benefits of the Paragon Medical acquisition. This unaudited pro forma financial information is presented for informational purposes only and is not indicative of future operations or results had the Paragon Medical acquisition been completed as of January 1, 2017.

The unaudited pro forma financial results include certain adjustments for debt service costs and additional depreciation and amortization expense based upon the fair value step-up and estimated useful lives of Paragon Medical depreciable fixed assets and definite-life amortizable assets acquired. The provision for income taxes has also been adjusted for all periods, based upon the foregoing adjustments to historical results.



	Three Months Ended September 30, 2018			Nine Months Ended September 30, 2018
Pro forma net sales	$	205,683		$	626,414
Pro forma net loss	$	(12,035	)	$	(32,129	)
Basic net loss per share	$	(0.42	)	$	(1.16	)
Diluted net loss per share	$	(0.42	)	$	(1.16	)

Other Acquisitions

Bridgemedica, LLC. On February 22, 2018, we completed the acquisition of 100% of the assets of Bridgemedica, LLC (“Bridgemedica”). For accounting purposes, Bridgemedica meets the definition of a business and has been accounted for as a business combination. Bridgemedica is a medical device company that provides concept to supply solutions through design, development engineering, and manufacturing. Operating results of Bridgemedica are reported in our Life Sciences group after the acquisition date. We have finalized the purchase price allocation with no material changes to the initial allocation.

Southern California Technical Arts, Inc. On August 9, 2018, we completed the acquisition of 100% of the capital stock of Southern California Technical Arts, Inc. (“Technical Arts”). For accounting purposes, Technical Arts meets the definition of a business and has been accounted for as a business combination. Technical Arts is an industrial machining company that manufactures tight tolerance metal components and assemblies. The acquisition of Technical Arts expands our presence in the aerospace and defense end market. Operating results of Technical Arts are reported in our Power Solutions group after the acquisition date. We have finalized the purchase price allocation with no material changes to the initial allocation.

Segment Information

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Segment Information

Management has concluded that Life Sciences, which is focused on growth in the medical end market, primarily in the orthopaedics and medical/surgical end markets; Mobile Solutions, which is focused on growth in the general industrial and automotive end markets; and Power Solutions, which is focused on growth in the electrical and aerospace and defense end markets, constitute our operating segments. Life Sciences, Mobile Solutions, and Power Solutions are considered operating segments as each engages in business activities for which it earns revenues and incurs expenses, discrete financial information is available for each, and this is the level at which the Chief Operating Decision Maker (“CODM”) reviews discrete financial information for purposes of allocating resources and assessing performance.

Segment Results

The following tables present results of operations by reportable segment.



	Life Sciences		Mobile Solutions		Power Solutions		Corporate and Consolidations				Total
Three Months Ended September 30, 2019
Net sales	$	94,011	$	73,071	$	47,430	$	(615	)	(a)	$	213,897
Income (loss) from operations	9,402		3,681		3,351		(8,762		)		7,672
Interest expense											(14,733		)
Other											(98		)
Loss before benefit for income taxes and share of net income from joint venture											$	(7,159	)
Three Months Ended September 30, 2018
Net sales	$	78,363	$	81,805	$	46,082	$	(567	)	(a)	$	205,683
Income (loss) from operations	6,717		4,657		2,706		(8,199		)		5,881
Interest expense											(18,608		)
Other											(6,932		)
Loss before benefit for income taxes and share of net income from joint venture											$	(19,659	)



	Life Sciences		Mobile Solutions		Power Solutions		Corporate and Consolidations				Total
Nine Months Ended September 30, 2019
Net sales	$	271,351	$	230,590	$	148,480	$	(1,602	)	(a)	$	648,819
Income (loss) from operations	22,553		11,880		12,857		(30,919		)		16,371
Interest expense											(42,492		)
Other											(3,583		)
Loss before provision for income taxes and share of net income from joint venture											$	(29,704	)
Nine Months Ended September 30, 2018
Net sales	$	168,716	$	259,678	$	144,584	$	(1,798	)	(a)	$	571,180
Income (loss) from operations	12,962		21,822		13,939		(39,440		)		9,283
Interest expense											(46,592		)
Other											(21,444		)
Loss before benefit for income taxes and share of net income from joint venture											$	(58,753	)

_______________________________


(a)	Includes elimination of intersegment transactions occurring during the ordinary course of business.

Total assets by reportable segment as of September 30, 2019, and December 31, 2018, were as follows:



	Total Assets
	September 30, 2019		December 31, 2018
Life Sciences	$	817,153	$	802,770
Mobile Solutions	377,571		356,387
Power Solutions	314,516		297,947
Corporate and Consolidations	44,505		45,797
Total	$	1,553,745	$	1,502,901

Inventories

9 Months Ended

Sep. 30, 2019

Inventory Disclosure [Abstract]

Inventories

Inventories are comprised of the following amounts:



	September 30, 2019		December 31, 2018
Raw materials	$	52,776	$	52,930
Work in process	46,548		42,578
Finished goods	27,508		27,107
Total inventories	$	126,832	$	122,615

Goodwill

9 Months Ended

Sep. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

The following table shows changes in the carrying amount of goodwill by reportable segment.



	Life Sciences			Power Solutions			Total
Balance as of December 31, 2018	$	344,947		$	94,505		$	439,452
Currency impacts/Other	(1,970		)	(202		)	(2,172		)
Balance as of September 30, 2019	$	342,977		$	94,303		$	437,280

In 2018, Mobile Solutions recorded an impairment loss on goodwill. As of September 30, 2019, no goodwill was recorded at Mobile Solutions.

Based on the closing price of a share of our common stock as of September 30, 2019, our market capitalization was at a level that is less than the net book value of our stockholders’ equity. A prolonged or significant decline in market capitalization could be an indicator of additional goodwill impairment. We concluded that our market capitalization as of September 30, 2019, was not at a level that would require us to perform a goodwill impairment assessment during the period. We will continue to monitor our market capitalization to determine if an indicator of impairment exists in subsequent periods.

During 2018, as a result of our annual goodwill impairment analysis performed during the fourth quarter of 2018, we recorded an impairment of $109.1 million in our Power Solutions group. Subsequent to the impairment, at December 31, 2018, Power Solutions reported a goodwill balance of $94.5 million. Given the carrying value of the Power Solutions group was equal to its fair value at December 31, 2018, as a result of the 2018 goodwill impairment, if actual performance of the Power Solutions group falls short of expected results, additional material impairment charges may be required. During the third quarter of 2019, we assessed for triggering events that would signify the need to perform an impairment test and concluded there were no triggering events during the period. Our annual impairment analysis will be completed as of October 1, 2019.

Intangible Assets, Net

9 Months Ended

Sep. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Intangible Assets, Net

The following table shows changes in the carrying amount of intangible assets, net by reportable segment.



	Life Sciences			Mobile Solutions			Power Solutions			Total
Balance as of December 31, 2018	$	244,365		$	35,892		$	95,991		$	376,248
Amortization	(24,860		)	(2,640		)	(8,245		)	(35,745		)
Other	8			2			—			10
Balance as of September 30, 2019	$	219,513		$	33,254		$	87,746		$	340,513

Investment in Joint Venture

9 Months Ended

Sep. 30, 2019

Equity Method Investments and Joint Ventures [Abstract]

Investment in Joint Venture

We own a 49% investment in Wuxi Weifu Autocam Precision Machinery Company, Ltd. (the “JV”), a joint venture located in Wuxi, China. The JV is jointly controlled and managed, and we account for it under the equity method.

The following table shows changes in our investment in the JV.



Balance as of December 31, 2018	$	20,364
Share of earnings	345
Foreign currency translation loss	(832		)
Balance as of September 30, 2019	$	19,877

During the fourth quarter of 2018, as a result of changing market conditions, the fair value of the JV was assessed and we recorded an impairment of $16.6 million against our investment in the JV. The fair value assessment was significantly affected by changes in our assessment of future growth rates. It is reasonably possible that material deviation of future performance from the estimates used in the 2018 valuation could result in additional impairment to our investment in the JV in subsequent periods. During the third quarter of 2019, we assessed for triggering events that would signify the need to perform an impairment test and concluded there were no triggering events during the period.

We recognized sales to the JV of less than $0.1 million and $0.1 million during the three and nine months ended September 30, 2019, respectively, and less than $0.1 million and $0.2 million for the three and nine months ended September 30, 2018, respectively.

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Our effective tax rate was 17.9% and (5.2)% for the three months and nine months ended September 30, 2019, respectively. Our effective tax rate was 28.4% and 20.8% for the three months and nine months ended September 30, 2018, respectively. Our effective tax rate for the nine months ended September 30, 2019, differs from the U.S. federal statutory tax rate of 21% principally due to a discrete tax charge of $6.0 million related to final tax regulations published by the Department of the Treasury and Internal Revenue Service on February 4, 2019, as well as the minimum tax on global intangible low-tax income (“GILTI”). The effective tax rate for the three months ended September 30, 2019, is impacted by the minimum tax on GILTI. Our 2018 effective tax rate differed from the U.S. federal statutory tax rate of 21% due to permanent differences including GILTI and earnings outside the United States, which were taxed at different rates than the U.S. federal statutory rate of 21%.

Debt

9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Debt

Collectively, our credit facility is comprised of a term loan with a face amount of $545.0 million, maturing on October 19, 2022 (the “Senior Secured Term Loan”); a term loan with a face amount of $300.0 million, maturing on April 3, 2021 (the Incremental Term Loan”); and the Senior Secured Revolver. The credit facility is collateralized by all of our assets.

The following table presents debt balances as of September 30, 2019, and December 31, 2018.



	September 30, 2019		December 31, 2018
Senior Secured Term Loan	$	527,750	$	532,063
Incremental Term Loan	270,000		279,000
Senior Secured Revolver	71,323		38,720
International lines of credit and other loans	9,897		9,810
Total principal	878,970		859,593
Less—current maturities of long-term debt	25,601		31,280
Principal, net of current portion	853,369		828,313
Less—unamortized debt issuance costs	11,621		16,842
Long-term debt, net of current portion	$	841,748	$	811,471

We capitalized interest costs of $0.4 million and $0.3 million in the three months ended September 30, 2019 and 2018, respectively, and $1.5 million and $0.8 million in the nine months ended September 30, 2019 and 2018, respectively, related to construction in progress.

Senior Secured Term Loan

Outstanding borrowings under the Senior Secured Term Loan bear interest at the greater of 0.75% or one-month London Interbank Offered Rate (“LIBOR”) plus an applicable margin of 3.75%. At September 30, 2019, the Senior Secured Term Loan bore interest at 5.80%.

Incremental Term Loan

Outstanding borrowings under the Incremental Term Loan bear interest at one-month LIBOR plus an applicable margin of 3.25%. At September 30, 2019, the Incremental Term Loan bore interest of 5.30%.

Senior Secured Revolver

Outstanding borrowings under the Senior Secured Revolver bear interest on a variable rate structure with borrowings bearing interest at either one-month LIBOR plus an applicable margin of 3.50% or the prime lending rate plus an applicable margin of 2.50%. At September 30, 2019, the weighted average interest rate on outstanding borrowings under the Senior Secured Revolver was 5.73%. We pay a commitment fee of 0.50% for unused capacity under the Senior Secured Revolver.

In March 2019, we amended our existing credit facility (the “March 2019 amendment”) to amend the defined terms within the credit facility. In June 2019, we amended our existing credit facility (the “June 2019 amendment”) to reduce the maximum capacity under the Senior Secured Revolver to $110.0 million, reduce the total available capacity to $100.0 million, and modify the consolidated net leverage ratio, as defined in the credit facility agreement, which is utilized for certain financial covenants. We paid $0.8 million and $0.2 million of debt issuance costs related to the March 2019 amendment and June 2019 amendment, respectively, which were recorded as a direct reduction to the carrying amount of the associated long-term debt. Additionally, $2.7 million of unamortized debt issuance costs associated with the March 2019 amendment to the existing credit facility were written off.

We had $71.3 million outstanding under the Senior Secured Revolver at September 30, 2019. Total available capacity under the Senior Secured Revolver was $100.0 million as of September 30, 2019, with $16.7 million available for future borrowings after reductions for outstanding letters of credit and outstanding borrowings as of September 30, 2019. Our credit facility is subject to certain financial covenants based on a consolidated net leverage ratio. The financial covenants are effective when we have outstanding borrowings under our Senior Secured Revolver on the last day of any fiscal quarter, become more restrictive over time, and are dependent upon our operational and financial performance. If our operational or financial performance does not improve in line with our expectations, we may be required to take actions to reduce expenditures and decrease our net indebtedness to maintain compliance in future periods. We were in compliance with all covenants under our credit facility at September 30, 2019.

As discussed in Note 1, the outstanding amounts under our Senior Secured Revolver are recognized as a current liability as of October 20, 2019.

Derivative Instruments and Hedging Activities

In February 2019, we entered into a $700.0 million amortizing notional amount fixed-rate interest rate swap agreement to manage the interest rate risk associated with our long-term variable-rate debt until 2022. The fixed-rate interest rate swap agreement calls for us to receive interest monthly at a variable rate equal to one-month LIBOR and to pay interest monthly at a fixed rate of 2.4575%. Refer to Note 16 for further discussion of the interest rate swap agreement.

Leases

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Leases

We adopted ASC 842 on January 1, 2019, and elected the modified retrospective approach in which the new standard is applied to all leases existing at the date of adoption through a cumulative-effect adjustment of less than $0.1 million to retained deficit. Consequently, financial information is not updated, and the disclosures required under the new standard are not provided for periods prior to January 1, 2019. As part of the adoption, we elected the package of practical expedients, the short-term lease exemption, and the practical expedient to not separate lease and non-lease components. Accordingly, we accounted for our existing operating leases as operating leases under the new standard, without reassessing (a) whether the contracts contain a lease under ASC 842, (b) whether classification of the operating leases would be different in accordance with ASC 842, or (c) whether any unamortized initial direct costs would have met the definition of initial direct costs in ASC 842 at lease commencement.

We determine whether an arrangement is a lease at inception. Right-of-use (“ROU”) lease assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU lease assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. When the implicit rate is not readily determinable, we use the estimated incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Amortization of ROU lease assets is recognized in expense on a straight-line basis over the lease term.

Short-term leases are leases having a term of twelve months or less. We recognize short-term leases on a straight-line basis and do not record a related lease asset or liability for such leases. Finance lease ROU assets consist of equipment used in the manufacturing process with terms greater than twelve months to seven years. Operating lease ROU assets consist of the following:


•	Equipment used in the manufacturing process as well as office equipment with terms greater than twelve months to seven years; and


•	Manufacturing plants and office facilities with terms greater than twelve months to 25 years.

The following table presents components of lease expense for the three and nine months ended September 30, 2019:



	Financial Statement Line Item	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019
Lease cost:
Finance lease cost
Amortization of right-of-use assets	Depreciation and amortization	$	360	$	1,043
Interest expense	Interest expense	75		184
Operating lease cost	Cost of sales and selling, general and administrative expense	3,461		10,294
Short-term lease cost ⁽¹⁾	Cost of sales and selling, general and administrative expense	131		342
Total lease cost		$	4,027	$	11,863

_______________________________

(1) Excludes expenses related to leases with a lease term of one month or less.

The following table presents the lease-related assets and liabilities recorded on the balance sheet as of September 30, 2019:



	Financial Statement Line Item	September 30, 2019
Lease assets and liabilities:
Assets
Operating lease assets	Operating lease right-of-use assets	$	67,885
Finance lease assets	Property, plant and equipment, net	14,268
Total lease assets		$	82,153

Liabilities
Current liabilities
Operating lease liabilities	Current portion of operating lease liabilities	$	7,047
Finance lease liabilities	Other current liabilities	2,839
Non-current liabilities
Operating lease liabilities	Operating lease liabilities, net of current portion	68,479
Finance lease liabilities	Other non-current liabilities	9,268
Total lease liabilities		$	87,633

The following table contains supplemental information related to leases for the nine months ended September 30, 2019:



Supplemental Cash Flows Information	Nine Months Ended September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from finance leases	$	184
Operating cash flows from operating leases	16,506
Financing cash flows from finance leases	2,520
Right-of-use assets obtained in exchange for new operating lease liabilities	$	8,677

As of September 30, 2019, the weighted average remaining lease term and weighted-average discount rate for finance and operating leases was as follows:

The maturities of lease liabilities greater than twelve months as of September 30, 2019, is as follows:



	Operating Leases		Finance Leases
2019 ⁽¹⁾	$	3,506	$	881
2020	12,106		3,106
2021	11,218		3,095
2022	10,927		2,880
2023	9,384		1,991
Thereafter	65,383		896
Total future minimum lease payments	112,524		12,849
Less: imputed interest	36,998		742
Total lease liabilities	$	75,526	$	12,107


(1)	For the period from October 1, 2019, to December 31, 2019.

As of September 30, 2019, we have an additional operating lease commitment that would require us to pay a total of approximately $27.5 million base rent payments over the lease term of 15 years. We are expected to commence base rent payments during the third quarter of 2020.

The following table presents the future minimum lease payments under operating leases with initial or non-cancelable lease terms in excess of one year prior to adoption of ASC 842 as reported in the 2018 Annual Report.



Year Ending December 31,
2019	$	13,337
2020	11,515
2021	10,557
2022	10,293
2023	8,752
Thereafter	53,945
Total minimum payments	$	108,399

During the three and nine months ended September 30, 2018, we recognized rent expense of $4.5 million and $9.0 million, respectively.

Leases


•	Equipment used in the manufacturing process as well as office equipment with terms greater than twelve months to seven years; and


•	Manufacturing plants and office facilities with terms greater than twelve months to 25 years.

The following table presents components of lease expense for the three and nine months ended September 30, 2019:



	Financial Statement Line Item	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019
Lease cost:
Finance lease cost
Amortization of right-of-use assets	Depreciation and amortization	$	360	$	1,043
Interest expense	Interest expense	75		184
Operating lease cost	Cost of sales and selling, general and administrative expense	3,461		10,294
Short-term lease cost ⁽¹⁾	Cost of sales and selling, general and administrative expense	131		342
Total lease cost		$	4,027	$	11,863

_______________________________

(1) Excludes expenses related to leases with a lease term of one month or less.

The following table presents the lease-related assets and liabilities recorded on the balance sheet as of September 30, 2019:



	Financial Statement Line Item	September 30, 2019
Lease assets and liabilities:
Assets
Operating lease assets	Operating lease right-of-use assets	$	67,885
Finance lease assets	Property, plant and equipment, net	14,268
Total lease assets		$	82,153

Liabilities
Current liabilities
Operating lease liabilities	Current portion of operating lease liabilities	$	7,047
Finance lease liabilities	Other current liabilities	2,839
Non-current liabilities
Operating lease liabilities	Operating lease liabilities, net of current portion	68,479
Finance lease liabilities	Other non-current liabilities	9,268
Total lease liabilities		$	87,633

The following table contains supplemental information related to leases for the nine months ended September 30, 2019:



Supplemental Cash Flows Information	Nine Months Ended September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from finance leases	$	184
Operating cash flows from operating leases	16,506
Financing cash flows from finance leases	2,520
Right-of-use assets obtained in exchange for new operating lease liabilities	$	8,677

As of September 30, 2019, the weighted average remaining lease term and weighted-average discount rate for finance and operating leases was as follows:

The maturities of lease liabilities greater than twelve months as of September 30, 2019, is as follows:



	Operating Leases		Finance Leases
2019 ⁽¹⁾	$	3,506	$	881
2020	12,106		3,106
2021	11,218		3,095
2022	10,927		2,880
2023	9,384		1,991
Thereafter	65,383		896
Total future minimum lease payments	112,524		12,849
Less: imputed interest	36,998		742
Total lease liabilities	$	75,526	$	12,107


(1)	For the period from October 1, 2019, to December 31, 2019.



Year Ending December 31,
2019	$	13,337
2020	11,515
2021	10,557
2022	10,293
2023	8,752
Thereafter	53,945
Total minimum payments	$	108,399

During the three and nine months ended September 30, 2018, we recognized rent expense of $4.5 million and $9.0 million, respectively.

Restructuring and Integration

9 Months Ended

Sep. 30, 2019

Restructuring and Related Activities [Abstract]

Restructuring and Integration

The following tables present restructuring and integration charges incurred for the three months ended September 30, 2018, and the nine months ended September 30, 2019 and 2018. There were no restructuring and integration charges incurred for the three months ended September 30, 2019.



				Three Months Ended September 30, 2018
	Life Sciences			Mobile Solutions		Power Solutions		Corporate and Consolidations		Total
Severance and other employee costs	$	(260	)	$	—	$	—	$	—	$	(260	)
Site closure and other associated costs	—			51		—		—		51
Total	(260		)	$	51	$	—	$	—	$	(209	)



			Nine Months Ended September 30, 2019
	Life Sciences		Mobile Solutions			Power Solutions		Corporate and Consolidations		Total
Severance and other employee costs	$	—	$	—		$	—	$	—	$	—
Site closure and other associated costs	—		(12		)	—		—		(12		)
Total	$	—	$	(12	)	$	—	$	—	$	(12	)

			Nine Months Ended September 30, 2018
	Life Sciences		Mobile Solutions			Power Solutions		Corporate and Consolidations		Total
Severance and other employee costs	$	1,336	$	—		$	—	$	728	$	2,064
Site closure and other associated costs	—		73			—		—		73
Total	$	1,336	$	73		$	—	$	728	$	2,137

The following table summarizes restructuring and integration reserve activity for the nine months ended September 30, 2019.



	Reserve Balance as of December 31, 2018		Charges			Non-cash Adjustments		Cash Reductions			Reserve Balance as of September 30, 2019
Severance and other employee costs	$	1,122	$	—		$	—	$	(524	)	$	598
Site closure and other associated costs	24		(12		)	—		(12		)	—
Total	$	1,146	$	(12	)	$	—	$	(536	)	$	598

The amount accrued for restructuring and integration costs represents what we expect to pay over the next 1.5 years. We expect to pay $0.4 million within the next twelve months.

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Brazil ICMS Tax Matter Prior to the acquisition of Autocam Corporation in 2014 (“Autocam”), Autocam’s Brazilian subsidiary (“Autocam Brazil”) received notification from the Brazilian tax authority regarding ICMS (state value added tax or “VAT”) tax credits claimed on intermediary materials (e.g., tooling and perishable items) used in the manufacturing process. The Brazilian tax authority notification disallowed state ICMS tax credits claimed on intermediary materials based on the argument that these items are not intrinsically related to the manufacturing processes. Autocam Brazil filed an administrative defense with the Brazilian tax authority arguing, among other matters, that it should qualify for an ICMS tax credit, contending that the intermediary materials are directly related to the manufacturing process. We believe that we have substantial legal and factual defenses, and we plan to defend our interests in this matter vigorously. The matter encompasses several lawsuits filed with the Brazilian courts requesting declaratory actions that no tax is due or seeking a stay of execution on the collection of the tax. In 2018, we obtained a favorable decision in one of the declaratory actions for which the period for appeal has expired. We have filed actions in each court requesting dismissal of the matter based on the earlier court action. Although we anticipate a favorable resolution to all matters, we can provide no assurances that we will be successful in achieving dismissal of all pending cases. While we believe a loss is not probable, we estimate the range of possible losses related to this assessment is from $0 to $6.0 million. No amount was accrued at September 30, 2019, for this matter. We are entitled to indemnification from the former shareholders of Autocam, subject to the limitations and procedures set forth in the agreement and plan of merger relating to the Autocam acquisition. Management believes the indemnification would include amounts owed for the tax, interest, and penalties related to this matter. Securities Offering Matter On November 1, 2019, Erie County Employees’ Retirement System, on behalf of a purported class of plaintiffs, filed a complaint in the Supreme Court of the State of New York, County of New York, against the Company, certain of the Company’s current and former officers and directors, and each of the underwriters involved in the Company’s public offering and sale of 14,375,000 shares of its common stock pursuant to a preliminary prospectus supplement, dated September 10, 2018, a final prospectus supplement, dated September 13, 2018, and a base prospectus, dated April 19, 2017, relating to the Company’s effective shelf registration statement on Form S-3 (File No. 333-216737) (the “Offering”). The complaint alleges violations of Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 in connection with the Offering. The plaintiffs seek to represent a class of stockholders who purchased shares of the Company’s common stock in the Offering. The complaint seeks unspecified monetary damages and other relief. The Company believes the complaint and allegations to be without merit and intends to vigorously defend itself against these actions. The Company is unable at this time to determine whether the outcome of the litigation would have a material impact on the Company’s financial position, results of operations, or cash flows. All Other Legal Matters All other legal proceedings are of an ordinary and routine nature and are incidental to our operations. Management believes that such proceedings should not, individually or in the aggregate, have a material adverse effect on our business, financial condition, results of operations, or cash flows. In making that determination, we analyze the facts and circumstances of each case at least quarterly in consultation with our attorneys and determine a range of reasonably possible outcomes.

Revenue from Contracts with Customers

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

Revenue from Contracts with Customers

Revenue is recognized when control of the good or service is transferred to the customer either at a point in time or, in limited circumstances, as our services are rendered over time. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or services. Sales, value add, and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. Incidental items that are immaterial in the context of the contract are recognized as expense.

The following tables present sales to external customers by reportable segment.



	Three Months Ended September 30, 2019
	Life Sciences		Mobile Solutions		Power Solutions		Intersegment Sales Eliminations			Total
United States	$	79,429	$	40,147	$	38,750	$	(615	)	$	157,711
China	1,590		9,109		1,870		—			12,569
Brazil	—		9,414		72		—			9,486
Mexico	68		4,700		3,832		—			8,600
Germany	6,504		1,768		17		—			8,289
Switzerland	2,985		1,094		15		—			4,094
Other	3,435		6,839		2,874		—			13,148
Total net sales	$	94,011	$	73,071	$	47,430	$	(615	)	$	213,897



			Three Months Ended September 30, 2018
	Life Sciences		Mobile Solutions		Power Solutions		Intersegment Sales Eliminations			Total
United States	$	63,869	$	46,341	$	38,137	$	(567	)	$	147,780
China	2,405		11,111		1,696		—			15,212
Mexico	90		6,570		2,254		—			8,914
Germany	7,321		1,415		17		—			8,753
Brazil	—		8,200		107		—			8,307
Poland	2,107		1,215		6		—			3,328
Switzerland	—		1,420		47		—			1,467
Other	2,571		5,533		3,818		—			11,922
Total net sales	$	78,363	$	81,805	$	46,082	$	(567	)	$	205,683



			Nine Months Ended September 30, 2019
	Life Sciences		Mobile Solutions		Power Solutions		Intersegment Sales Eliminations			Total
United States	$	222,001	$	129,116	$	120,445	$	(1,602	)	$	469,960
China	5,155		27,580		5,306		—			38,041
Germany	23,836		4,490		54		—			28,380
Brazil	—		27,432		221		—			27,653
Mexico	312		15,144		10,776		—			26,232
Switzerland	9,759		3,606		56		—			13,421
Other	10,288		23,222		11,622		—			45,132
Total net sales	$	271,351	$	230,590	$	148,480	$	(1,602	)	$	648,819



			Nine Months Ended September 30, 2018
	Life Sciences		Mobile Solutions		Power Solutions		Intersegment Sales Eliminations			Total
United States	$	142,863	$	144,138	$	120,189	$	(1,798	)	$	405,392
China	3,843		34,273		4,140		—			42,256
Mexico	429		21,042		8,799		—			30,270
Brazil	29		27,722		157		—			27,908
Germany	11,138		4,500		24		—			15,662
Switzerland	3,827		3,915		35		—			7,777
Poland	1		5,485		23		—			5,509
Other	6,586		18,603		11,217		—			36,406
Total net sales	$	168,716	$	259,678	$	144,584	$	(1,798	)	$	571,180

Deferred Revenue

The following table provides information about contract liabilities from contracts with customers.



	Deferred Revenue
Balance at January 1, 2019	$	2,974
Balance at September 30, 2019	$	3,268

Revenue recognized during the three and nine months ended September 30, 2019, from amounts included in deferred revenue at the beginning of the period for performance obligations satisfied or partially satisfied during the period, was $1.4 million and $3.0 million, respectively.

Transaction Price Allocated to Future Performance Obligations

We are required to disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of September 30, 2019, unless our contracts meet one of the practical expedients. Our contracts met the practical expedient for a performance obligation that is part of a contract that has an original expected duration of one year or less.

Sales Concentration

During the three months ended September 30, 2019, we recognized sales from a single customer of $23.7 million, or 11.1% of consolidated net sales. During the nine months ended September 30, 2019, we recognized sales from a single customer of $68.7 million, or 10.6% of consolidated net sales. Revenues from this customer are in our Life Sciences and Power Solutions groups. No customers represented more than 10% of our net sales during the three and nine months ended September 30, 2018.

Shared-Based Compensation

9 Months Ended

Sep. 30, 2019

Share-based Payment Arrangement [Abstract]

Shared-Based Compensation

Share-Based Compensation

The following table lists the components of share-based compensation expense by type of award.



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Stock options	$	371		$	173		$	732		$	531
Restricted stock	446			388			1,407			1,244
Performance share units	334			530			991			1,650
Change in estimate of share-based award vesting	(1,275		)	(802		)	(1,275		)	(802		)
Share-based compensation expense	$	(124	)	$	289		$	1,855		$	2,623

Stock Options

During the nine months ended September 30, 2019, we granted options to purchase 210,400 shares to certain key employees. The weighted average grant date fair value of the options granted during the nine months ended September 30, 2019, was $2.77 per share. The fair value of our options cannot be determined by market value because they are not traded in an open market. Accordingly, we utilized the Black Scholes financial pricing model to estimate the fair value.

The following table shows the weighted average assumptions relevant to determining the fair value of stock options granted in 2019.



	2019
Expected term	6 years
Risk free interest rate	2.47	%
Dividend yield	3.53	%
Expected volatility	49.53	%
Expected forfeiture rate	4.00	%

The expected term is derived from using the simplified method of determining stock option terms as described under the Staff Accounting Bulletin Topic 14, Share-based payment. The simplified method was used because sufficient historical stock option exercise experience was not available, primarily due to the transformation of the management structure over the past several years.

The average risk-free interest rate is derived from United States Department of Treasury published interest rates of daily yield curves for the same time period as the expected term.

The expected dividend yield is derived by a mathematical formula which uses the expected annual dividends over the expected term divided by the fair market value of our common stock at the grant date.

The expected volatility rate is derived from our actual common stock historical volatility over the same time period as the expected term. The volatility rate is derived by a mathematical formula utilizing daily closing price data.

The forfeiture rate is determined from examining the historical pre-vesting forfeiture patterns of past option issuances to key employees. While the forfeiture rate is not an input of the Black Scholes model for determining the fair value of the options, it is an important determinant of stock option compensation expense to be recorded.

The following table presents stock option activity for the nine months ended September 30, 2019.



	Number of Options (in thousands)		Weighted- Average Exercise Price (per share)		Weighted- Average Remaining Contractual Term (years)	Aggregate Intrinsic Value
Outstanding at January 1, 2019	771		$	15.17
Granted	210		7.93
Exercised	(5	)	4.42			$	7
Forfeited or expired	(139	)	15.61
Outstanding at September 30, 2019	837		$	13.34	6.0	$	—	⁽¹⁾
Exercisable at September 30, 2019	570		$	14.24	4.6	$	—	⁽¹⁾

_______________________________


(1)	The aggregate intrinsic value is the sum of intrinsic values for each exercisable individual option grant. The intrinsic value is the amount by which the closing market price of our stock at September 30, 2019, was greater than the exercise price of any individual option grant.

Restricted Stock

During the nine months ended September 30, 2019, we granted 309,234 restricted stock awards to non-executive directors, officers and certain other key employees. The shares of restricted stock granted during the nine months ended September 30, 2019, vest pro-rata over three years for officers and certain other key employees and over one year for non-executive directors. We determined the fair value of the shares awarded by using the closing price of our common stock as of the date of grant. The weighted average grant date value of restricted stock granted in the nine months ended September 30, 2019, was $7.85 per share. Total grant-date fair value of restricted stock that vested in the nine months ended September 30, 2019, was $2.6 million.

The following table presents the status of unvested restricted stock awards as of September 30, 2019, and changes during the nine months then ended.



	Nonvested Restricted Shares (in thousands)		Weighted Average Grant-Date Fair Value (per share)
Nonvested at January 1, 2019	146		$	22.07
Granted	309		7.85
Vested	(144	)	18.14
Forfeited	(79	)	10.09
Nonvested at September 30, 2019	232		$	9.62

Performance Share Units

Performance Share Units (“PSUs”) are a form of long-term incentive compensation awarded to executive officers and certain other key employees designed to directly align the interests of employees to the interests of our stockholders, and to create long-term stockholder value. PSUs granted in 2019 were made pursuant to the NN, Inc. 2016 Omnibus Incentive Plan and a Performance Share Unit Agreement (the “2016 Omnibus Agreement”). Some PSUs are based on total shareholder return (“TSR Awards”), and other PSUs are based on return on invested capital (“ROIC Awards”).

The TSR Awards vest, if at all, upon our achieving a specified relative total shareholder return, which will be measured against the total shareholder return of the S&P SmallCap 600 Index during specified performance periods as defined in the 2016 Omnibus Agreement. The ROIC Awards vest, if at all, upon our achieving a specified average return on invested capital during the performance periods. Each performance period generally begins on January 1 of the year of grant and ends 36 months later on December 31.

We recognize compensation expense over the performance period in which the performance and market conditions are measured. If the PSUs do not vest at the end of the performance periods, then the PSUs will expire automatically. Upon vesting, the PSUs will be settled by the issuance of shares of our common stock, subject to the award recipient’s continued employment. The actual number of shares of common stock to be issued to each award recipient at the end of the performance periods will be interpolated between a threshold and maximum payout amount based on actual performance results. No dividends will be paid on outstanding PSUs during the performance period; however, dividend equivalents will be paid based on the number of shares of common stock that are ultimately earned at the end of the performance periods.

With respect to the TSR Awards, a participant will earn 50% of the target number of PSUs for “Threshold Performance,” 100% of the target number of PSUs for “Target Performance,” and 150% of the target number of PSUs for “Maximum Performance.” With respect to the ROIC Awards, a participant will earn 35% of the target number of PSUs for “Threshold Performance,” 100% of the target number of PSUs for “Target Performance,” and 150% of the target number of PSUs for “Maximum Performance. For performance levels falling between the values shown below, the percentages will be determined by interpolation.

The following table presents the goals with respect to TSR Awards and ROIC Awards granted in 2019.



TSR Awards:	Threshold Performance (50% of Shares)		Target Performance (100% of Shares)		Maximum Performance (150% of Shares)
2019 grants	35th Percentile		50th Percentile		75th Percentile

ROIC Awards:	Threshold Performance (35% of Shares)		Target Performance (100% of Shares)		Maximum Performance (150% of Shares)
2019 grants ⁽¹⁾	4.7	%	5.8	%	7.0	%


(1)	For the ROIC Awards granted in 2019, the denominator of the calculation is different than in prior years, and therefore the target percentages are not comparable to historical target percentages.

We estimate the grant date fair value of TSR Awards using the Monte Carlo simulation model, as the total shareholder return metric is considered a market condition under ASC Topic 718, Compensation – stock compensation. The grant date fair value of ROIC Awards is based on the closing price of a share of our common stock on the date of grant.

The following table presents the number of PSUs granted and the grant date fair value in the period presented.



	TSR Awards			ROIC Awards
Award Year	Shares (in thousands)	Grant Date Fair Value (per share)		Shares (in thousands)	Grant Date Fair Value (per share)
2019	136	$	9.28	174	$	7.93

We recognize expense for ROIC Awards based on the probable outcome of the associated performance condition. We generally recognize an expense for ROIC Awards based on the Target Performance threshold of 100% because, at the date of grant, the Target Performance is the probable level of performance achievement.

The following table presents the status of unvested PSUs as of September 30, 2019, and changes during the nine months then ended.



	Nonvested TSR Awards				Nonvested ROIC Awards
	Shares (in thousands)		Weighted Average Grant-Date Fair Value (per share)		Shares (in thousands)		Weighted Average Grant-Date Fair Value (per share)
Nonvested at January 1, 2019	94		$	26.84	100		$	24.39
Granted	136		9.28		174		7.93
Forfeited	(139	)	16.76		(164	)	14.20
Nonvested at September 30, 2019	91		$	16.03	110		$	13.53

Net Income (Loss) Per Share

9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

Net Income (Loss) Per Share



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Numerator:
Net loss	$	(5,597	)	$	(13,784	)	$	(30,894	)	$	(44,796	)
Denominator:
Weighted average shares outstanding	42,038			28,688			42,013			27,784
Per common share net loss:
Basic net loss per share	$	(0.13	)	$	(0.48	)	$	(0.74	)	$	(1.61	)
Diluted net loss per share	$	(0.13	)	$	(0.48	)	$	(0.74	)	$	(1.61	)
Cash dividends declared per share	$	0.07		$	0.07		$	0.21		$	0.21

The calculation of diluted net loss per share for the three and nine months ended September 30, 2019, excludes 0.8 million and 0.6 million, respectively, of potentially dilutive stock options, which had the effect of being anti-dilutive. The calculation of diluted net loss per share for the three and nine months ended September 30, 2018, excludes 0.8 million and 0.8 million, respectively, of potentially dilutive stock options, which had the effect of being anti-dilutive. Given the net loss for the three and nine months ended September 30, 2019 and 2018, all options are considered anti-dilutive and were excluded from the calculation of diluted net loss per share.

Fair Value Measurements

9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair value is an exit price representing the expected amount that an entity would receive to sell an asset or pay to transfer a liability in an orderly transaction with market participants at the measurement date. We followed consistent methods and assumptions to estimate fair values as more fully described in the 2018 Annual Report.

Fair value principles prioritize valuation inputs across three broad levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the assumptions used to measure assets and liabilities at fair value. An asset or liability’s classification within the various levels is determined based on the lowest level input that is significant to the fair value measurement.

Our financial instruments that are subject to fair value disclosure consist of cash and cash equivalents, accounts receivable, accounts payable, derivatives, and long-term debt. As of September 30, 2019, the carrying values of these financial instruments approximated fair value. The fair value of floating-rate debt approximates the carrying amount as interest rates are based on short-term maturities.

Derivative Financial Instruments

We manage our exposure to fluctuations in interest rates using a mix of fixed and variable rate debt. On February 8, 2019, we entered into a $700.0 million fixed-rate interest rate swap agreement that changed the LIBOR-based portion of the interest rate on a portion of our variable rate debt to a fixed rate of 2.4575% (the “interest rate swap”). The term of the interest rate swap is from the effective date of February 12, 2019, through the termination date of October 19, 2022 (the “interest rate swap term”). The interest rate swap effectively mitigates our exposures to the risks and variability of changes in LIBOR.

The notional amount of the interest rate swap will decrease over the interest rate swap term as follows:



	Notional Amount
February 12, 2019 - December 30, 2020	$	700,000
December 31, 2020 - December 30, 2021	466,667
December 31, 2021 - October 19, 2022	233,333

The objective of the interest rate swap is to eliminate the variability of cash flows in interest payments on the first $700.0 million of variable rate debt attributable to changes in benchmark one-month LIBOR interest rates. The hedged risk is the interest rate risk exposure to changes in interest payments, attributable to changes in benchmark one-month LIBOR interest rates over the interest rate swap term. If one-month LIBOR is greater than the minimum percentage under the Senior Secured Term Loan, the changes in cash flows of the interest rate swap are expected to exactly offset changes in cash flows of the variable rate debt. The interest rate swap is designated as a cash flow hedge.

As of September 30, 2019, we reported a $12.0 million loss, net of tax, in accumulated other comprehensive income related to the interest rate swap.

The following shows the liabilities measured at fair value on a recurring basis for the interest rate swap as of September 30, 2019.



	Fair Value Measurements as of September 30, 2019
Description	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Derivative liability - other current liabilities	$	—	$	5,719	$	—
Derivative liability - other non-current liabilities	—		9,514		—
Total	$	—	$	15,233	$	—

The inputs for determining fair value of the interest rate swap are classified as Level 2 inputs. Level 2 fair value is based on estimates using standard pricing models. These standard pricing models use inputs which are derived from or corroborated by observable market data such as interest rate yield curves, index forward curves, discount curves, and volatility surfaces. Counterparty to this derivative contract is a highly rated financial institution which we believe carries only a minimal risk of nonperformance.

As of December 31, 2018, we had no interest rate swap agreements or other derivative financial instruments outstanding.

Fixed Rate Debt

The fair value of our outstanding fixed-rate debt included in the “International lines of credit and other loans” line item within Note 9 to these Notes to Condensed Consolidated Financial Statements was $11.3 million and $10.4 million as of September 30, 2019 and December 31, 2018, respectively. These fair values represent Level 2 under the three-tier hierarchy described above. The book value of our outstanding fixed-rate debt included in the “International lines of credit and other loans” line item within Note 9 to these Notes to Condensed Consolidated Financial Statements was $9.9 million and $9.8 million as of September 30, 2019 and December 31, 2018, respectively.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Prior Periods' Financial Statement Revision Prior Periods' Financial Statement Revision

9 Months Ended

Sep. 30, 2019

Accounting Changes and Error Corrections [Abstract]

Prior Periods' Financial Statement Revision

Prior Periods' Financial Statement Revisions

As further described in Note 1, the Company is revising previously issued financial statements to correct for immaterial prior period tax misstatements. The following table presents the effect of the correction of the misstatements and the resulting revision on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).



	Nine Months Ended September 30, 2018
	As Originally Reported			Adjustment			As Revised
Income tax benefit (expense)	$	12,732		$	(519	)	$	12,213
Net income (loss)	(44,277		)	(519		)	(44,796		)
Comprehensive income (loss)	(58,787		)	(519		)	(59,306		)
Basic net income (loss) per share	$	(1.59	)	$	(0.02	)	$	(1.61	)
Diluted net income (loss) per share	$	(1.59	)	$	(0.02	)	$	(1.61	)

The following table presents the effect of the correction of the misstatements on the Consolidated Balance Sheet as of December 31, 2018.



	As of December 31, 2018
	As Originally Reported			Adjustment			As Revised
Income tax receivable	$	946		$	1,331		$	2,277
Total current assets	296,871			1,331			298,202
Total assets	1,501,570			1,331			1,502,901
Deferred tax liabilities	93,482			(1,644		)	91,838
Total liabilities	1,083,275			(1,644		)	1,081,631
Retained (deficit) earnings	(62,046		)	2,975			(59,071		)
Total stockholders' equity	418,295			2,975			421,270
Total liabilities and stockholders' equity	1,501,570			1,331			1,502,901

Although the misstatements had no impact on net cash provided by (used in) operating, investing or financing cash flows in the corresponding unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2018, they did impact amounts within operating activities which has been corrected for in the accompanying unaudited Condensed Consolidated Statements of Cash Flows. The accompanying footnotes have also been corrected to reflect the impact of the revisions.

The Company will effect the revisions of its previously issued 2018 and 2017 annual financial statements, and relevant unaudited interim quarterly financial information, in connection with the prospective issuance of its Annual Report on Form 10-K for the year ended December 31, 2019.

Interim Financial Statements (Policies)	9 Months Ended
Interim Financial Statements (Policies)	Sep. 30, 2019
Quarterly Financial Information Disclosure [Abstract]
Nature of Business	Nature of Business NN, Inc. is a global diversified industrial company that combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for the medical, aerospace and defense, electrical, automotive, and general industrial markets. As used in this Quarterly Report on Form 10-Q (this “Quarterly Report), the terms “NN,” the “Company,” “we,” “our,” or “us” refer to NN, Inc., and its subsidiaries.
Basis of Presentation	Basis of Presentation In accordance with Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date of the issuance of these unaudited interim financial statements. The Company’s existing revolving line of credit, which has a maximum capacity of $110.0 million, matures on October 19, 2020 (the “Senior Secured Revolver”). The Company leverages such line of credit, along with cash generated from operations, to fund operations and working capital and had $71.5 million of outstanding borrowings as of November 6, 2019. Based on our current and projected use of the facility, as well as cash flows to be generated from operations and investing activities, we do not anticipate that we will be able to repay the outstanding borrowings when they become due in October 2020 without refinancing the line of credit or obtaining new financing. The Company has and continues to make efforts to obtain new financing; however, there is no assurance that we will obtain sufficient financing on commercially reasonable terms, if at all, before the outstanding amounts would be required to be repaid. This condition raises substantial doubt about the Company’s ability to continue as a going concern within one year after the date of issuance of these financial statements. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. The accompanying condensed consolidated financial statements have not been audited, except that the Condensed Consolidated Balance Sheet as of December 31, 2018, was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018 (the “2018 Annual Report”), which we filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 18, 2019. In management’s opinion, the accompanying unaudited condensed consolidated financial statements reflect all adjustments necessary to fairly state our results of operations for the three and nine months ended September 30, 2019 and 2018; financial position as of September 30, 2019, and December 31, 2018; and cash flows for the nine months ended September 30, 2019 and 2018, on a basis consistent with our audited consolidated financial statements other than the adoption of new accounting standards, such as the new lease standard (see Note 10). These adjustments are of a normal recurring nature and are, in the opinion of management, necessary to state fairly the Company’s financial position and operating results for the interim periods. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted from the interim financial statements presented in this Quarterly Report. These unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and accompanying notes included in the 2018 Annual Report. The results for the three and nine months ended September 30, 2019, are not necessarily indicative of results for the year ending December 31, 2019, or any other future periods. Except for per share data or as otherwise indicated, all U.S. dollar amounts presented in the tables in these Notes to Condensed Consolidated Financial Statements are in thousands.
Prior Periods' Financial Statement Revisions	Prior Periods’ Financial Statement Revisions In connection with the preparation of our interim financial statements for the nine months ended September 30, 2019, we identified tax accounting misstatements in our previously issued 2018 Annual Report. Such misstatements relate to the tax accounting associated with the 2018 impairment of our joint venture as well as other immaterial tax misstatements. We assessed the materiality of the misstatements on prior periods’ financial statements in accordance with SEC Staff Accounting Bulletin (“SAB”) Topic 1.M, Materiality, codified in Accounting Standards Codification (“ASC”) Topic 250, Accounting Changes and Error Corrections, (“ASC 250”) and concluded that the misstatements were not material to the prior annual or interim periods. However, the Company has determined that it will revise its previously issued 2018 and 2017 annual financial statements, and relevant interim periods, to correct for these misstatements. In connection with such revision, the Company will correct for an immaterial tax misstatement that originated in 2017 and had been previously corrected for as an out of period adjustment in 2018. In connection with the filing of this Quarterly Report, we have revised the accompanying Consolidated Statements of Operations and Comprehensive Income (Loss) and our Consolidated Statements of Cash Flows for the nine months ended September 30, 2018, and have reflected the impact of the revision on our Consolidated Balance Sheet as of December 31, 2018. Refer to Note 17 for the effect of the correction of the misstatements on each of the financial statements noted above.
Accounting Standards	Accounting Standards Recently Adopted Leases. On January 1, 2019, we adopted Accounting Standards Codification (“ASC”) 842, Leases, which superseded ASC 840, Leases. We adopted ASC 842 utilizing the modified retrospective transition approach; therefore, historical financial information and disclosures do not reflect the new standard and will continue to be presented under the previous lease accounting guidance. Under the modified retrospective transition method, the cumulative effect of the initial adoption adjustment of less than $0.1 million was recognized to the opening balance of retained deficit as of January 1, 2019. As part of the adoption, we elected the package of practical expedients, the short-term lease exemption, and the practical expedient to not separate lease and non-lease components. We recorded lease-related assets and liabilities to our balance sheet for leases with terms greater than twelve months that were classified as operating leases and not previously recorded on our balance sheet. See Note 10 for the required disclosures related to ASC 842. Derivatives and Hedging. In August 2017, the Financial Accounting Standards Board (“FASB”) issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, (“ASU 2017-12”). ASU 2017-12 provides new rules that expand the hedging strategies that qualify for hedge accounting. The new rules also allow additional time to complete hedge effectiveness testing and allow qualitative assessments subsequent to initial quantitative tests if there is a supportable expectation that the hedge will remain highly effective. We adopted the guidance on January 1, 2019. We have applied the new rules to 2019 hedging activities as disclosed in Note 16 to these condensed consolidated financial statements. The new guidance has no effect on our historical financial statements. Effects of Tax Reform in Other Comprehensive Income. In February 2018, the FASB issued guidance related to the impacts of the U.S. Tax Cuts and Jobs Act of 2017 (“Tax Act”). Under existing U.S. GAAP, the effects of changes in tax rates and laws on deferred tax balances are recorded as a component of income tax expense in the period in which the law was enacted. When deferred tax balances related to items originally recorded in accumulated other comprehensive income (“AOCI”) are adjusted, certain tax effects become stranded in AOCI. The FASB issued ASU 2018-2, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, that permits reclassification of certain income tax effects of the Tax Act from AOCI to retained earnings. The guidance also requires certain disclosures about stranded tax effects. The new guidance was effective for us on January 1, 2019. We adopted the new guidance at the beginning of the period of adoption. The new guidance had no effect on our financial statements. Accounting Standards Not Yet Adopted Fair Value Disclosures. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), that modifies fair value disclosure requirements. The new guidance could impact us by streamlining disclosures of Level 3 fair value measurements. The modified disclosures are effective for us beginning in the first quarter of 2020, with early adoption allowed. ASU 2018-13 changes disclosures only and does not impact our financial condition, results of operations, or cash flows. We are in the process of evaluating the effects of this guidance on our fair value disclosures. Internal-Use Software. In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force) (“ASU 2018-15”), that provides guidance on a customer’s accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by the vendor. Under the new guidance, customers will apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. ASU 2018-15 is effective for us on January 1, 2020, using either a prospective or retrospective approach and with early adoption permitted. We are in the process of evaluating the effects of this guidance on our financial statements, but do not expect the adoption to have a material impact. Financial Instruments - Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which modifies the measurement of expected credit losses on certain financial instruments and the timing of when such losses are recorded. ASU 2016-13 is effective for us on January 1, 2020, using a modified retrospective approach, with early adoption permitted. We are in the process of evaluating the effects of this guidance on our financial statements, but do not expect the adoption to have a material impact.

Acquisitions (Tables)

9 Months Ended

Sep. 30, 2019

Business Combinations [Abstract]

Business Acquisition, Pro Forma Information

The provision for income taxes has also been adjusted for all periods, based upon the foregoing adjustments to historical results.



	Three Months Ended September 30, 2018			Nine Months Ended September 30, 2018
Pro forma net sales	$	205,683		$	626,414
Pro forma net loss	$	(12,035	)	$	(32,129	)
Basic net loss per share	$	(0.42	)	$	(1.16	)
Diluted net loss per share	$	(0.42	)	$	(1.16	)

Segment Information (Tables)

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Segment Information

The following tables present results of operations by reportable segment.



	Life Sciences		Mobile Solutions		Power Solutions		Corporate and Consolidations				Total
Three Months Ended September 30, 2019
Net sales	$	94,011	$	73,071	$	47,430	$	(615	)	(a)	$	213,897
Income (loss) from operations	9,402		3,681		3,351		(8,762		)		7,672
Interest expense											(14,733		)
Other											(98		)
Loss before benefit for income taxes and share of net income from joint venture											$	(7,159	)
Three Months Ended September 30, 2018
Net sales	$	78,363	$	81,805	$	46,082	$	(567	)	(a)	$	205,683
Income (loss) from operations	6,717		4,657		2,706		(8,199		)		5,881
Interest expense											(18,608		)
Other											(6,932		)
Loss before benefit for income taxes and share of net income from joint venture											$	(19,659	)



	Life Sciences		Mobile Solutions		Power Solutions		Corporate and Consolidations				Total
Nine Months Ended September 30, 2019
Net sales	$	271,351	$	230,590	$	148,480	$	(1,602	)	(a)	$	648,819
Income (loss) from operations	22,553		11,880		12,857		(30,919		)		16,371
Interest expense											(42,492		)
Other											(3,583		)
Loss before provision for income taxes and share of net income from joint venture											$	(29,704	)
Nine Months Ended September 30, 2018
Net sales	$	168,716	$	259,678	$	144,584	$	(1,798	)	(a)	$	571,180
Income (loss) from operations	12,962		21,822		13,939		(39,440		)		9,283
Interest expense											(46,592		)
Other											(21,444		)
Loss before benefit for income taxes and share of net income from joint venture											$	(58,753	)

_______________________________


(a)	Includes elimination of intersegment transactions occurring during the ordinary course of business.

Total assets by reportable segment as of September 30, 2019, and December 31, 2018, were as follows:



	Total Assets
	September 30, 2019		December 31, 2018
Life Sciences	$	817,153	$	802,770
Mobile Solutions	377,571		356,387
Power Solutions	314,516		297,947
Corporate and Consolidations	44,505		45,797
Total	$	1,553,745	$	1,502,901

Inventories (Tables)

9 Months Ended

Sep. 30, 2019

Inventory Disclosure [Abstract]

Summary of Inventories

Inventories are comprised of the following amounts:



	September 30, 2019		December 31, 2018
Raw materials	$	52,776	$	52,930
Work in process	46,548		42,578
Finished goods	27,508		27,107
Total inventories	$	126,832	$	122,615

Goodwill (Tables)

9 Months Ended

Sep. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Changes in Carrying Amount of Goodwill

The following table shows changes in the carrying amount of goodwill by reportable segment.



	Life Sciences			Power Solutions			Total
Balance as of December 31, 2018	$	344,947		$	94,505		$	439,452
Currency impacts/Other	(1,970		)	(202		)	(2,172		)
Balance as of September 30, 2019	$	342,977		$	94,303		$	437,280

Intangible Assets, Net (Tables)

9 Months Ended

Sep. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Carrying Amount of Intangible Assets Net

The following table shows changes in the carrying amount of intangible assets, net by reportable segment.



	Life Sciences			Mobile Solutions			Power Solutions			Total
Balance as of December 31, 2018	$	244,365		$	35,892		$	95,991		$	376,248
Amortization	(24,860		)	(2,640		)	(8,245		)	(35,745		)
Other	8			2			—			10
Balance as of September 30, 2019	$	219,513		$	33,254		$	87,746		$	340,513

Investment in Joint Venture (Tables)

9 Months Ended

Sep. 30, 2019

Equity Method Investments and Joint Ventures [Abstract]

Summarized Activity Related to Investment in Joint Venture

The following table shows changes in our investment in the JV.



Balance as of December 31, 2018	$	20,364
Share of earnings	345
Foreign currency translation loss	(832		)
Balance as of September 30, 2019	$	19,877

Debt (Tables)

9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Summary of Debt

The following table presents debt balances as of September 30, 2019, and December 31, 2018.



	September 30, 2019		December 31, 2018
Senior Secured Term Loan	$	527,750	$	532,063
Incremental Term Loan	270,000		279,000
Senior Secured Revolver	71,323		38,720
International lines of credit and other loans	9,897		9,810
Total principal	878,970		859,593
Less—current maturities of long-term debt	25,601		31,280
Principal, net of current portion	853,369		828,313
Less—unamortized debt issuance costs	11,621		16,842
Long-term debt, net of current portion	$	841,748	$	811,471

Leases (Tables)

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Lease, Cost

The following table contains supplemental information related to leases for the nine months ended September 30, 2019:



Supplemental Cash Flows Information	Nine Months Ended September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from finance leases	$	184
Operating cash flows from operating leases	16,506
Financing cash flows from finance leases	2,520
Right-of-use assets obtained in exchange for new operating lease liabilities	$	8,677

As of September 30, 2019, the weighted average remaining lease term and weighted-average discount rate for finance and operating leases was as follows:

The following table presents components of lease expense for the three and nine months ended September 30, 2019:



	Financial Statement Line Item	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019
Lease cost:
Finance lease cost
Amortization of right-of-use assets	Depreciation and amortization	$	360	$	1,043
Interest expense	Interest expense	75		184
Operating lease cost	Cost of sales and selling, general and administrative expense	3,461		10,294
Short-term lease cost ⁽¹⁾	Cost of sales and selling, general and administrative expense	131		342
Total lease cost		$	4,027	$	11,863

_______________________________

(1) Excludes expenses related to leases with a lease term of one month or less.

Assets and Liabilities, Lessee

The following table presents the lease-related assets and liabilities recorded on the balance sheet as of September 30, 2019:



	Financial Statement Line Item	September 30, 2019
Lease assets and liabilities:
Assets
Operating lease assets	Operating lease right-of-use assets	$	67,885
Finance lease assets	Property, plant and equipment, net	14,268
Total lease assets		$	82,153

Liabilities
Current liabilities
Operating lease liabilities	Current portion of operating lease liabilities	$	7,047
Finance lease liabilities	Other current liabilities	2,839
Non-current liabilities
Operating lease liabilities	Operating lease liabilities, net of current portion	68,479
Finance lease liabilities	Other non-current liabilities	9,268
Total lease liabilities		$	87,633

Lessee, Operating Lease, Liability, Maturity

The maturities of lease liabilities greater than twelve months as of September 30, 2019, is as follows:



	Operating Leases		Finance Leases
2019 ⁽¹⁾	$	3,506	$	881
2020	12,106		3,106
2021	11,218		3,095
2022	10,927		2,880
2023	9,384		1,991
Thereafter	65,383		896
Total future minimum lease payments	112,524		12,849
Less: imputed interest	36,998		742
Total lease liabilities	$	75,526	$	12,107


(1)	For the period from October 1, 2019, to December 31, 2019.

Finance Lease, Liability, Maturity

The maturities of lease liabilities greater than twelve months as of September 30, 2019, is as follows:



	Operating Leases		Finance Leases
2019 ⁽¹⁾	$	3,506	$	881
2020	12,106		3,106
2021	11,218		3,095
2022	10,927		2,880
2023	9,384		1,991
Thereafter	65,383		896
Total future minimum lease payments	112,524		12,849
Less: imputed interest	36,998		742
Total lease liabilities	$	75,526	$	12,107


(1)	For the period from October 1, 2019, to December 31, 2019.

Schedule of Future Minimum Rental Payments for Operating Leases



Year Ending December 31,
2019	$	13,337
2020	11,515
2021	10,557
2022	10,293
2023	8,752
Thereafter	53,945
Total minimum payments	$	108,399

Restructuring and Integration (Tables)

9 Months Ended

Sep. 30, 2019

Restructuring and Related Activities [Abstract]

Summary of Restructuring and Integration Charges and Reserve Activity



				Three Months Ended September 30, 2018
	Life Sciences			Mobile Solutions		Power Solutions		Corporate and Consolidations		Total
Severance and other employee costs	$	(260	)	$	—	$	—	$	—	$	(260	)
Site closure and other associated costs	—			51		—		—		51
Total	(260		)	$	51	$	—	$	—	$	(209	)



			Nine Months Ended September 30, 2019
	Life Sciences		Mobile Solutions			Power Solutions		Corporate and Consolidations		Total
Severance and other employee costs	$	—	$	—		$	—	$	—	$	—
Site closure and other associated costs	—		(12		)	—		—		(12		)
Total	$	—	$	(12	)	$	—	$	—	$	(12	)

			Nine Months Ended September 30, 2018
	Life Sciences		Mobile Solutions			Power Solutions		Corporate and Consolidations		Total
Severance and other employee costs	$	1,336	$	—		$	—	$	728	$	2,064
Site closure and other associated costs	—		73			—		—		73
Total	$	1,336	$	73		$	—	$	728	$	2,137

The following table summarizes restructuring and integration reserve activity for the nine months ended September 30, 2019.



	Reserve Balance as of December 31, 2018		Charges			Non-cash Adjustments		Cash Reductions			Reserve Balance as of September 30, 2019
Severance and other employee costs	$	1,122	$	—		$	—	$	(524	)	$	598
Site closure and other associated costs	24		(12		)	—		(12		)	—
Total	$	1,146	$	(12	)	$	—	$	(536	)	$	598

Revenue from Contracts with Customers (Tables)

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

Summary of Revenue from Contracts with Customers

The following tables present sales to external customers by reportable segment.



	Three Months Ended September 30, 2019
	Life Sciences		Mobile Solutions		Power Solutions		Intersegment Sales Eliminations			Total
United States	$	79,429	$	40,147	$	38,750	$	(615	)	$	157,711
China	1,590		9,109		1,870		—			12,569
Brazil	—		9,414		72		—			9,486
Mexico	68		4,700		3,832		—			8,600
Germany	6,504		1,768		17		—			8,289
Switzerland	2,985		1,094		15		—			4,094
Other	3,435		6,839		2,874		—			13,148
Total net sales	$	94,011	$	73,071	$	47,430	$	(615	)	$	213,897



			Three Months Ended September 30, 2018
	Life Sciences		Mobile Solutions		Power Solutions		Intersegment Sales Eliminations			Total
United States	$	63,869	$	46,341	$	38,137	$	(567	)	$	147,780
China	2,405		11,111		1,696		—			15,212
Mexico	90		6,570		2,254		—			8,914
Germany	7,321		1,415		17		—			8,753
Brazil	—		8,200		107		—			8,307
Poland	2,107		1,215		6		—			3,328
Switzerland	—		1,420		47		—			1,467
Other	2,571		5,533		3,818		—			11,922
Total net sales	$	78,363	$	81,805	$	46,082	$	(567	)	$	205,683



			Nine Months Ended September 30, 2019
	Life Sciences		Mobile Solutions		Power Solutions		Intersegment Sales Eliminations			Total
United States	$	222,001	$	129,116	$	120,445	$	(1,602	)	$	469,960
China	5,155		27,580		5,306		—			38,041
Germany	23,836		4,490		54		—			28,380
Brazil	—		27,432		221		—			27,653
Mexico	312		15,144		10,776		—			26,232
Switzerland	9,759		3,606		56		—			13,421
Other	10,288		23,222		11,622		—			45,132
Total net sales	$	271,351	$	230,590	$	148,480	$	(1,602	)	$	648,819



			Nine Months Ended September 30, 2018
	Life Sciences		Mobile Solutions		Power Solutions		Intersegment Sales Eliminations			Total
United States	$	142,863	$	144,138	$	120,189	$	(1,798	)	$	405,392
China	3,843		34,273		4,140		—			42,256
Mexico	429		21,042		8,799		—			30,270
Brazil	29		27,722		157		—			27,908
Germany	11,138		4,500		24		—			15,662
Switzerland	3,827		3,915		35		—			7,777
Poland	1		5,485		23		—			5,509
Other	6,586		18,603		11,217		—			36,406
Total net sales	$	168,716	$	259,678	$	144,584	$	(1,798	)	$	571,180

Summary of Contract Liabilities from Contracts with Customers

The following table provides information about contract liabilities from contracts with customers.



	Deferred Revenue
Balance at January 1, 2019	$	2,974
Balance at September 30, 2019	$	3,268

Shared-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2019

Share-based Payment Arrangement [Abstract]

Components of Share-Based Compensation Expense by Type of Award

The following table lists the components of share-based compensation expense by type of award.



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Stock options	$	371		$	173		$	732		$	531
Restricted stock	446			388			1,407			1,244
Performance share units	334			530			991			1,650
Change in estimate of share-based award vesting	(1,275		)	(802		)	(1,275		)	(802		)
Share-based compensation expense	$	(124	)	$	289		$	1,855		$	2,623

Weighted Average Assumptions Relevant to Determining the Fair Value at the Dates of Grant and Stock Option Modification

The following table shows the weighted average assumptions relevant to determining the fair value of stock options granted in 2019.



	2019
Expected term	6 years
Risk free interest rate	2.47	%
Dividend yield	3.53	%
Expected volatility	49.53	%
Expected forfeiture rate	4.00	%

Reconciliation of Option Activity

The following table presents stock option activity for the nine months ended September 30, 2019.



	Number of Options (in thousands)		Weighted- Average Exercise Price (per share)		Weighted- Average Remaining Contractual Term (years)	Aggregate Intrinsic Value
Outstanding at January 1, 2019	771		$	15.17
Granted	210		7.93
Exercised	(5	)	4.42			$	7
Forfeited or expired	(139	)	15.61
Outstanding at September 30, 2019	837		$	13.34	6.0	$	—	⁽¹⁾
Exercisable at September 30, 2019	570		$	14.24	4.6	$	—	⁽¹⁾

_______________________________


(1)	The aggregate intrinsic value is the sum of intrinsic values for each exercisable individual option grant. The intrinsic value is the amount by which the closing market price of our stock at September 30, 2019, was greater than the exercise price of any individual option grant.

Reconciliation of Restricted Stock Option Activity

The following table presents the status of unvested restricted stock awards as of September 30, 2019, and changes during the nine months then ended.



	Nonvested Restricted Shares (in thousands)		Weighted Average Grant-Date Fair Value (per share)
Nonvested at January 1, 2019	146		$	22.07
Granted	309		7.85
Vested	(144	)	18.14
Forfeited	(79	)	10.09
Nonvested at September 30, 2019	232		$	9.62

Schedule of Performance Based Awards Goals with Respect to TSR and ROIC

The following table presents the goals with respect to TSR Awards and ROIC Awards granted in 2019.



TSR Awards:	Threshold Performance (50% of Shares)		Target Performance (100% of Shares)		Maximum Performance (150% of Shares)
2019 grants	35th Percentile		50th Percentile		75th Percentile

ROIC Awards:	Threshold Performance (35% of Shares)		Target Performance (100% of Shares)		Maximum Performance (150% of Shares)
2019 grants ⁽¹⁾	4.7	%	5.8	%	7.0	%


(1)	For the ROIC Awards granted in 2019, the denominator of the calculation is different than in prior years, and therefore the target percentages are not comparable to historical target percentages.

Schedule of Number of Awards Granted and Grant Date Fair Value of Each Award in Periods

The following table presents the number of PSUs granted and the grant date fair value in the period presented.



	TSR Awards			ROIC Awards
Award Year	Shares (in thousands)	Grant Date Fair Value (per share)		Shares (in thousands)	Grant Date Fair Value (per share)
2019	136	$	9.28	174	$	7.93

Summary of Status of Unvested PSU Awards

The following table presents the status of unvested PSUs as of September 30, 2019, and changes during the nine months then ended.



	Nonvested TSR Awards				Nonvested ROIC Awards
	Shares (in thousands)		Weighted Average Grant-Date Fair Value (per share)		Shares (in thousands)		Weighted Average Grant-Date Fair Value (per share)
Nonvested at January 1, 2019	94		$	26.84	100		$	24.39
Granted	136		9.28		174		7.93
Forfeited	(139	)	16.76		(164	)	14.20
Nonvested at September 30, 2019	91		$	16.03	110		$	13.53

Net Income (Loss) Per Share (Tables)

9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

Summary of Net Income (Loss) Per Share



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Numerator:
Net loss	$	(5,597	)	$	(13,784	)	$	(30,894	)	$	(44,796	)
Denominator:
Weighted average shares outstanding	42,038			28,688			42,013			27,784
Per common share net loss:
Basic net loss per share	$	(0.13	)	$	(0.48	)	$	(0.74	)	$	(1.61	)
Diluted net loss per share	$	(0.13	)	$	(0.48	)	$	(0.74	)	$	(1.61	)
Cash dividends declared per share	$	0.07		$	0.07		$	0.21		$	0.21

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Schedule of Notional Amounts of Outstanding Derivative Positions

The notional amount of the interest rate swap will decrease over the interest rate swap term as follows:



	Notional Amount
February 12, 2019 - December 30, 2020	$	700,000
December 31, 2020 - December 30, 2021	466,667
December 31, 2021 - October 19, 2022	233,333

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following shows the liabilities measured at fair value on a recurring basis for the interest rate swap as of September 30, 2019.



	Fair Value Measurements as of September 30, 2019
Description	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Derivative liability - other current liabilities	$	—	$	5,719	$	—
Derivative liability - other non-current liabilities	—		9,514		—
Total	$	—	$	15,233	$	—

Prior Periods' Financial Statement Revision (Tables)

9 Months Ended

Sep. 30, 2019

Accounting Changes and Error Corrections [Abstract]

Schedule of Correction of Misstatements and Revision on Consolidated Statements



	Nine Months Ended September 30, 2018
	As Originally Reported			Adjustment			As Revised
Income tax benefit (expense)	$	12,732		$	(519	)	$	12,213
Net income (loss)	(44,277		)	(519		)	(44,796		)
Comprehensive income (loss)	(58,787		)	(519		)	(59,306		)
Basic net income (loss) per share	$	(1.59	)	$	(0.02	)	$	(1.61	)
Diluted net income (loss) per share	$	(1.59	)	$	(0.02	)	$	(1.61	)

The following table presents the effect of the correction of the misstatements on the Consolidated Balance Sheet as of December 31, 2018.



	As of December 31, 2018
	As Originally Reported			Adjustment			As Revised
Income tax receivable	$	946		$	1,331		$	2,277
Total current assets	296,871			1,331			298,202
Total assets	1,501,570			1,331			1,502,901
Deferred tax liabilities	93,482			(1,644		)	91,838
Total liabilities	1,083,275			(1,644		)	1,081,631
Retained (deficit) earnings	(62,046		)	2,975			(59,071		)
Total stockholders' equity	418,295			2,975			421,270
Total liabilities and stockholders' equity	1,501,570			1,331			1,502,901

Interim Financial Statements - Additional Information (Detail) - USD ($)	Nov. 06, 2019	Sep. 30, 2019	Jun. 11, 2019	Jan. 01, 2019	Dec. 31, 2018	Jan. 01, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of new accounting principle of adoption				$ (51,000)		$ 17,000
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of new accounting principle of adoption				$ 100,000
Senior Secured Revolving Facility
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Senior debt		$ 71,323,000			$ 38,720,000
Maximum borrowing capacity			$ 110,000,000
Subsequent Event [Member] \| Senior Secured Revolving Facility
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Senior debt	$ 71,500,000

Acquisitions - Additional Information (Detail)	Aug. 09, 2018	May 07, 2018	Feb. 22, 2018
Paragon Medical Inc
Business Acquisition [Line Items]
Acquisition percentage		100.00%
Bridgemedica, LLC
Business Acquisition [Line Items]
Acquisition percentage			100.00%
Southern California Technical Arts, Inc.
Business Acquisition [Line Items]
Acquisition percentage	100.00%

Acquisitions Pro Forma Financial Results (Details) - Paragon Medical Inc - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018
Business Acquisition [Line Items]
Pro forma net sales	$ 205,683	$ 626,414
Pro forma net loss	$ (12,035)	$ (32,129)
Basic net loss per share (in dollars per share)	$ (0.42)	$ (1.16)
Diluted net loss per share (in dollars per share)	$ (0.42)	$ (1.16)

Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Segment Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Segment Reporting Information [Line Items]
Net sales	$ 213,897	$ 205,683	$ 648,819	$ 571,180
Income (loss) from operations	7,672	5,881	16,371	9,283
Interest expense	(14,733)	(18,608)	(42,492)	(46,592)
Other	(98)	(6,932)	(3,583)	(21,444)
Loss before (provision) benefit for income taxes and share of net income from joint venture	(7,159)	(19,659)	(29,704)	(58,753)
Total assets	1,553,745		1,553,745		$ 1,502,901
Life Sciences
Segment Reporting Information [Line Items]
Total assets	817,153		817,153		802,770
Mobile Solutions
Segment Reporting Information [Line Items]
Total assets	377,571		377,571		356,387
Power Solutions
Segment Reporting Information [Line Items]
Total assets	314,516		314,516		297,947
Corporate and Consolidations
Segment Reporting Information [Line Items]
Total assets	44,505		44,505		$ 45,797
Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Net sales	94,011	78,363	271,351	168,716
Income (loss) from operations	9,402	6,717	22,553	12,962
Operating Segments \| Mobile Solutions
Segment Reporting Information [Line Items]
Net sales	73,071	81,805	230,590	259,678
Income (loss) from operations	3,681	4,657	11,880	21,822
Operating Segments \| Power Solutions
Segment Reporting Information [Line Items]
Net sales	47,430	46,082	148,480	144,584
Income (loss) from operations	3,351	2,706	12,857	13,939
Corporate and Eliminations \| Corporate and Consolidations
Segment Reporting Information [Line Items]
Net sales	(615)	(567)	(1,602)	(1,798)
Income (loss) from operations	$ (8,762)	$ (8,199)	$ (30,919)	$ (39,440)

Inventories - Summary of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 52,776	$ 52,930
Work in process	46,548	42,578
Finished goods	27,508	27,107
Total inventories	$ 126,832	$ 122,615

Goodwill - Changes in Carrying Amount of Goodwill (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2018	Sep. 30, 2019
Goodwill [Roll Forward]
Beginning Balance		$ 439,452,000
Currency impacts/Other		(2,172,000)
Ending Balance	$ 439,452,000	437,280,000
Mobile Solutions
Goodwill [Roll Forward]
Ending Balance		0
Power Solutions
Goodwill [Roll Forward]
Beginning Balance		94,505,000
Currency impacts/Other		(202,000)
Ending Balance	94,505,000	94,303,000
Goodwill, impairment loss	109,100,000	0
Life Sciences
Goodwill [Roll Forward]
Beginning Balance		344,947,000
Currency impacts/Other		(1,970,000)
Ending Balance	$ 344,947,000	$ 342,977,000

Goodwill - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended
Goodwill - Additional Information (Details) - USD ($)	Dec. 31, 2018	Sep. 30, 2019
Goodwill [Line Items]
Goodwill	$ 439,452,000	$ 437,280,000
Mobile Solutions
Goodwill [Line Items]
Goodwill		0
Power Solutions
Goodwill [Line Items]
Goodwill, impairment loss	109,100,000	0
Goodwill	$ 94,505,000	$ 94,303,000

Intangible Assets, Net - Summary of Carrying Amount of Intangible Assets by Segment (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($)
Finite-lived Intangible Assets [Roll Forward]
Beginning Balance	$ 376,248
Amortization	(35,745)
Other	10
Ending balance	340,513
Mobile Solutions
Finite-lived Intangible Assets [Roll Forward]
Beginning Balance	35,892
Amortization	(2,640)
Other	2
Ending balance	33,254
Power Solutions
Finite-lived Intangible Assets [Roll Forward]
Beginning Balance	95,991
Amortization	(8,245)
Other	0
Ending balance	87,746
Life Sciences
Finite-lived Intangible Assets [Roll Forward]
Beginning Balance	244,365
Amortization	(24,860)
Other	8
Ending balance	$ 219,513

Investment in Joint Venture - Additional Information (Detail) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Schedule of Equity Method Investments [Line Items]
Net sales	$ 213,897,000		$ 205,683,000	$ 648,819,000	$ 571,180,000
Joint Venture
Schedule of Equity Method Investments [Line Items]
Impairment charge		$ 16,600,000		$ 0
Wuxi Weifu Autocam Precision Machinery Company, Ltd.
Schedule of Equity Method Investments [Line Items]
Investment in joint venture	49.00%			49.00%
Product \| Joint Venture
Schedule of Equity Method Investments [Line Items]
Net sales				$ 100,000	$ 200,000
Product \| Joint Venture \| Maximum
Schedule of Equity Method Investments [Line Items]
Net sales	$ 100,000		$ 100,000

Investment in Joint Venture - Summarized Activity Related to Investment in Joint Venture (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Equity Method Investments [Roll Forward]
Beginning Balance			$ 20,364
Our share of cumulative earnings	$ 279	$ 266	345	$ 1,744
Ending Balance	19,877		19,877
Joint Venture
Equity Method Investments [Roll Forward]
Beginning Balance			20,364
Our share of cumulative earnings			345
Foreign currency translation gain			(832)
Ending Balance	$ 19,877		$ 19,877

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Effective tax rate from continuing operations	17.90%	28.40%	(5.20%)	20.80%
Change in tax rate, income tax expense (benefit)			$ 6.0

Debt - Summary of Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
International lines of credit and other loans	$ 9,897	$ 9,800
Total	878,970	859,593
Less current maturities of long-term debt	25,601	31,280
Principal, net of current portion	853,369	828,313
Less unamortized debt issuance costs	11,621	16,842
Long-term debt, net of current portion	841,748	811,471
Chinese
Debt Instrument [Line Items]
International lines of credit and other loans		9,810
Senior Secured Term Loan B
Debt Instrument [Line Items]
Senior debt	527,750	532,063
Incremental Term Loan
Debt Instrument [Line Items]
Senior debt	270,000	279,000
Senior Secured Revolving Facility
Debt Instrument [Line Items]
Senior debt	$ 71,323	$ 38,720

Debt - Additional Information (Detail) - USD ($)			3 Months Ended		9 Months Ended
Debt - Additional Information (Detail) - USD ($)	Jun. 11, 2019	Mar. 15, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Feb. 28, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Capitalized interest costs			$ 400,000	$ 300,000	$ 1,500,000	$ 800,000
Remaining borrowing capacity			16,700,000		16,700,000
Payments of debt issuance costs					1,016,000	$ 20,703,000
Senior Secured Term Loan B
Debt Instrument [Line Items]
Borrowings			545,000,000		$ 545,000,000
Interest rate during period					5.80%
Senior debt			$ 527,750,000		$ 527,750,000			$ 532,063,000
Senior Secured Term Loan B \| London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Applicable margin					3.75%
Senior Secured Term Loan B \| London Interbank Offered Rate (LIBOR) \| Minimum
Debt Instrument [Line Items]
Interest rate			0.75%		0.75%
Incremental Term Loan
Debt Instrument [Line Items]
Borrowings			$ 300,000,000		$ 300,000,000
Interest rate during period					5.30%
Senior debt			270,000,000		$ 270,000,000			279,000,000
Incremental Term Loan \| London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Applicable margin					3.25%
Senior Secured Revolving Facility
Debt Instrument [Line Items]
Interest rate during period					5.73%
Unused capacity, commitment fee percentage					0.50%
Principal available			100,000,000		$ 100,000,000
Senior debt			$ 71,323,000		$ 71,323,000			$ 38,720,000
Payments of debt issuance costs	$ 200,000	$ 800,000
Write off of deferred debt issuance cost		$ 2,700,000
Maximum borrowing capacity	$ 110,000,000
Senior Secured Revolving Facility \| London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Applicable margin					3.50%
Senior Secured Revolving Facility \| Prime Rate
Debt Instrument [Line Items]
Applicable margin					2.50%
Interest Rate Swap
Debt Instrument [Line Items]
Derivative, notional amount							$ 700,000,000
Derivative, fixed interest rate							2.4575%

Leases - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
Leases - Narrative (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2019	Jan. 01, 2019	Jan. 01, 2018
Lessee, Lease, Description [Line Items]
Cumulative effect of new accounting principle of adoption				$ (51)	$ 17
Lessee, operating lease, lease not yet commenced, amount			$ 27,500
Lessee, operating lease, lease not yet commenced, term of contract			15 years
Rent expense	$ 4,500	$ 9,000
Equipment \| Minimum
Lessee, Lease, Description [Line Items]
Lessee, finance lease, term of contract			12 months
Equipment \| Maximum
Lessee, Lease, Description [Line Items]
Lessee, finance lease, term of contract			7 years
Manufacturing Facility \| Minimum
Lessee, Lease, Description [Line Items]
Lessee, finance lease, term of contract			12 months
Manufacturing Facility \| Maximum
Lessee, Lease, Description [Line Items]
Lessee, finance lease, term of contract			25 years
Accounting Standards Update 2016-02
Lessee, Lease, Description [Line Items]
Cumulative effect of new accounting principle of adoption				100
Retained Earnings
Lessee, Lease, Description [Line Items]
Cumulative effect of new accounting principle of adoption				(51)	$ 17
Retained Earnings \| Accounting Standards Update 2016-02
Lessee, Lease, Description [Line Items]
Cumulative effect of new accounting principle of adoption				$ 100

Leases - Finance and Operating Lease Information (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Dec. 31, 2018
Finance lease cost
Amortization of right-of-use assets	$ 360	$ 1,043
Interest expense	75	184
Operating lease cost	3,461	10,294
Short-term lease cost	131	342
Total lease cost	4,027	11,863
Assets
Operating lease right-of-use assets	67,885	67,885	$ 0
Finance lease right-of-use assets	14,268	14,268
Lease, right-of-use asset	82,153	82,153
Current liabilities
Operating lease liabilities	7,047	7,047	0
Finance lease liabilities	2,839	2,839
Non-current liabilities
Operating lease liabilities	68,479	68,479	$ 0
Finance lease liabilities	9,268	9,268
Total lease liabilities	$ 87,633	$ 87,633

Leases - Supplemental Cash Flow Information (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($)
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from finance leases	$ 184
Operating cash flows from operating leases	16,506
Financing cash flows from finance leases	2,520
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 8,677

Leases - Weighted Average Remaining Lease Term and Discount Rate (Details)	Sep. 30, 2019
Operating Leases
Weighted-average remaining lease term (years)	4 years 11 months
Weighted-average discount rate	10 years 8 months
Finance Leases
Weighted-average remaining lease term (years)	2.30%
Weighted-average discount rate	7.80%

Leases - Future Minimum Lease Obligations After Adoption of 842 (Details) $ in Thousands	Sep. 30, 2019 USD ($)
Operating Leases
2019	$ 3,506
2020	12,106
2021	11,218
2022	10,927
2023	9,384
Thereafter	65,383
Total future minimum lease payments	112,524
Less: imputed interest	36,998
Total lease liabilities	75,526
Finance Leases
2019	881
2020	3,106
2021	3,095
2022	2,880
2023	1,991
Thereafter	896
Total future minimum lease payments	12,849
Less: imputed interest	742
Total lease liabilities	$ 12,107

Leases - Future Minimum Lease Obligations Before Adoption of 842 (Details) $ in Thousands	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 13,337
2020	11,515
2021	10,557
2022	10,293
2023	8,752
Thereafter	53,945
Total minimum payments	$ 108,399

Restructuring and Integration - Summary of Restructuring and Integration Charges and Reserve Activity (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Restructuring Cost and Reserve [Line Items]
Severance and other employee costs	$ (260)	$ 0	$ 2,064
Other	51	(12)	73
Restructuring Reserve [Roll Forward]
Reserve beginning balance		1,146
Charges	(209)	(12)	2,137
Non-cash Adjustments		0
Cash Reductions		(536)
Reserve ending balance		598
Severance and Other Employee Costs
Restructuring Reserve [Roll Forward]
Reserve beginning balance		1,122
Charges		0
Non-cash Adjustments		0
Cash Reductions		(524)
Reserve ending balance		598
Site Closure and Other Associated Costs
Restructuring Reserve [Roll Forward]
Reserve beginning balance		24
Charges		(12)
Non-cash Adjustments		0
Cash Reductions		(12)
Reserve ending balance		0
Operating Segments \| Mobile Solutions
Restructuring Cost and Reserve [Line Items]
Severance and other employee costs	0	0	0
Other	51	(12)	73
Restructuring Reserve [Roll Forward]
Charges	51	(12)	73
Operating Segments \| Power Solutions
Restructuring Cost and Reserve [Line Items]
Severance and other employee costs	0	0	0
Other	0	0	0
Restructuring Reserve [Roll Forward]
Charges	0	0	0
Operating Segments \| Life Sciences
Restructuring Cost and Reserve [Line Items]
Severance and other employee costs	(260)	0	1,336
Other	0	0	0
Restructuring Reserve [Roll Forward]
Charges	(260)	0	1,336
Corporate and Eliminations \| Corporate and Consolidations
Restructuring Cost and Reserve [Line Items]
Severance and other employee costs	0	0	728
Other	0	0	0
Restructuring Reserve [Roll Forward]
Charges	$ 0	$ 0	$ 728

Restructuring and Integration - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Restructuring and Related Activities [Abstract]
Restructuring and integration expense, net	$ 0	$ (209,000)	$ (12,000)	$ 2,137,000
Pay period for accrued restructuring and integration costs			1 year 5 months 25 days
Restructuring and related cost, expected cost remaining	$ 400,000		$ 400,000

Commitments and Contingencies - Additional Information (Detail) - USD ($)		3 Months Ended	9 Months Ended
	Nov. 01, 2019	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2019
Contingencies And Commitments [Line Items]
Amount accrued for estimation of loss				$ 0
Stock Issued During Period, Shares, New Issues		14,375,000	14,375,000
Minimum
Contingencies And Commitments [Line Items]
Possible loss estimated				0
Maximum
Contingencies And Commitments [Line Items]
Possible loss estimated				$ 6,000,000
Subsequent Event [Member]
Contingencies And Commitments [Line Items]
Stock Issued During Period, Shares, New Issues	14,375,000

Revenue from Contracts with Customers - Summary of Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue, Major Customer [Line Items]
Net sales	$ 213,897	$ 205,683	$ 648,819	$ 571,180
Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	(615)	(567)	(1,602)	(1,798)
United States
Revenue, Major Customer [Line Items]
Net sales	157,711	147,780	469,960	405,392
United States \| Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	(615)	(567)	(1,602)	(1,798)
Chinese
Revenue, Major Customer [Line Items]
Net sales	12,569	15,212	38,041	42,256
Chinese \| Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0	0	0
Mexico
Revenue, Major Customer [Line Items]
Net sales	8,600	8,914	26,232	30,270
Mexico \| Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0	0	0
Brazil
Revenue, Major Customer [Line Items]
Net sales	9,486	8,307	27,653	27,908
Brazil \| Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0	0	0
Germany
Revenue, Major Customer [Line Items]
Net sales	8,289	8,753	28,380	7,777
Germany \| Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0	0	0
Switzerland
Revenue, Major Customer [Line Items]
Net sales	4,094	1,467	13,421	5,509
Switzerland \| Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0	0	0
Poland
Revenue, Major Customer [Line Items]
Net sales		3,328
Poland \| Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales		0		0
Italy
Revenue, Major Customer [Line Items]
Net sales				15,662
Other Country
Revenue, Major Customer [Line Items]
Net sales	13,148	11,922	45,132	36,406
Other Country \| Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0	0	0
Mobile Solutions \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	73,071	81,805	230,590	259,678
Mobile Solutions \| United States \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	40,147	46,341	129,116	144,138
Mobile Solutions \| Chinese \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	9,109	11,111	27,580	34,273
Mobile Solutions \| Mexico \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	4,700	6,570	15,144	21,042
Mobile Solutions \| Brazil \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	9,414	8,200	27,432	27,722
Mobile Solutions \| Germany \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	1,768	1,415	4,490	4,500
Mobile Solutions \| Switzerland \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	1,094	1,420	3,606	3,915
Mobile Solutions \| Poland \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales		1,215		5,485
Mobile Solutions \| Other Country \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	6,839	5,533	23,222	18,603
Power Solutions \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	47,430	46,082	148,480	144,584
Power Solutions \| United States \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	38,750	38,137	120,445	120,189
Power Solutions \| Chinese \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	1,870	1,696	5,306	4,140
Power Solutions \| Mexico \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	3,832	2,254	10,776	8,799
Power Solutions \| Brazil \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	72	107	221	157
Power Solutions \| Germany \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	17	17	54	24
Power Solutions \| Switzerland \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	15	47	56	35
Power Solutions \| Poland \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales		6		23
Power Solutions \| Other Country \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	2,874	3,818	11,622	11,217
Life Sciences \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	94,011	78,363	271,351	168,716
Life Sciences \| United States \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	79,429	63,869	222,001	142,863
Life Sciences \| Chinese \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	1,590	2,405	5,155	3,843
Life Sciences \| Mexico \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	68	90	312	429
Life Sciences \| Brazil \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	0	0	0	29
Life Sciences \| Germany \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	6,504	7,321	23,836	11,138
Life Sciences \| Switzerland \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	2,985	0	9,759	3,827
Life Sciences \| Poland \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales		2,107		1
Life Sciences \| Other Country \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	$ 3,435	$ 2,571	$ 10,288	$ 6,586

Revenue from Contracts with Customers - Summary of Contract Liabilities from Contracts with Customers (Detail) $ in Thousands	Sep. 30, 2019 USD ($)
Contract with Customer, Liability [Abstract]
Deferred revenue, beginning balance	$ 2,974
Deferred revenue, ending balance	$ 3,268

Revenue from Contracts with Customers Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue, Major Customer [Line Items]
Amounts included in deferred revenue for performance obligations satisfied or partially satisfied	$ 1,400,000		$ 3,000,000
Major Customer
Revenue, Major Customer [Line Items]
Revenues	$ 23,700,000	$ 0	$ 68,700,000	$ 0
Major Customer \| Customer Concentration Risk \| Sales Revenue, Net
Revenue, Major Customer [Line Items]
Concentration risk, percentage	11.10%		10.60%

Shared-Based Compensation - Components of Share-Based Compensation Expense by Type of Award (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ (124)	$ 289	$ 1,855	$ 2,623
Stock Option Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	371	173	732	531
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	446	388	1,407	1,244
Performance Based Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	334	530	991	1,650
Change in Accounting Method Accounted for as Change in Estimate
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ (1,275)	$ (802)	$ (1,275)	$ (802)

Shared-Based Compensation - Additional Information (Detail) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2019 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)	210,400
Weighted average grant date fair value of the options granted (in dollars per share) \| $ / shares	$ 2.77
Total grant-date fair value of restricted stock \| $	$ 2.6
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units issued (in shares)	309,234
Fair value assumptions, exercise price (in dollars per share) \| $ / shares	$ 7.85
TSR Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units issued (in shares)	136,000
Percentage of shares issuable based on threshold performance	50.00%
Percentage of shares issuable based on target performance	100.00%
Percentage of shares issuable based on maximum performance	150.00%
ROIC Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units issued (in shares)	174,000
Percentage of shares issuable based on threshold performance	35.00%
Percentage of shares issuable based on target performance	100.00%
Percentage of shares issuable based on maximum performance	150.00%
Officers and Key Employees \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock awards granted vesting period	3 years
Non-executive Directors \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock awards granted vesting period	1 year

Shared-Based Compensation - Weighted Average Assumptions Relevant to Determining the Fair Value at the Dates of Grant and Stock Option Modification (Detail) - Stock Option Awards	9 Months Ended
	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years
Risk free interest rate	2.47%
Dividend yield	3.53%
Expected volatility	49.53%
Expected forfeiture rate	4.00%

Shared-Based Compensation - Reconciliation of Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2019
Number of Options (in thousands)
Beginning balance (in shares)	771,000
Granted (in shares)	210,400
Exercised (in shares)	(5,000)
Forfeitures (in shares)	(139,000)
Ending balance (in shares)	837,000
Options exercisable (in shares)	570,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Beginning balance (in dollars per share)	$ 15.17
Granted (in dollars per share)	7.93
Exercised (in dollars per share)	4.42
Forfeitures (in dollars per share)	15.61
Ending balance (in dollars per share)	13.34
Options exercisable (in dollars per share)	$ 14.24
Weighted-average remaining contractual term, outstanding	6 years 14 days
Weighted- average remaining contractual term, options exercisable	4 years 7 months
Aggregate intrinsic value, exercised	$ 7
Aggregate intrinsic value, outstanding	0
Aggregate intrinsic value, options exercisable	$ 0

Shared-Based Compensation - Reconciliation of Restricted Stock Option Activity (Detail)	9 Months Ended
	Sep. 30, 2019 $ / shares shares
Restricted Stock
Nonvested Shares (in thousands)
Nonvested restricted shares, beginning balance (in shares) \| shares	146,000
Nonvested restricted shares, granted (in shares) \| shares	309,234
Nonvested restricted shares, vested (in shares) \| shares	(144,000)
Nonvested restricted shares, forfeited (in shares) \| shares	(79,000)
Nonvested restricted shares, ending balance (in shares) \| shares	232,000
Weighted average grant-date fair value, beginning balance (in dollara per share) \| $ / shares	$ 22.07
Weighted average grant-date fair value, granted (in dollars per share) \| $ / shares	7.85
Weighted average grant-date fair value, vested (in dollars per share) \| $ / shares	18.14
Weighted average grant-date fair value, forfeited (in dollars per share) \| $ / shares	10.09
Weighted average grant-date fair value, ending balance (in dollars per share) \| $ / shares	$ 9.62
TSR Awards
Nonvested Shares (in thousands)
Nonvested restricted shares, beginning balance (in shares) \| shares	94,000
Nonvested restricted shares, granted (in shares) \| shares	136,000
Nonvested restricted shares, forfeited (in shares) \| shares	(139,000)
Nonvested restricted shares, ending balance (in shares) \| shares	91,000
Weighted average grant-date fair value, beginning balance (in dollara per share) \| $ / shares	$ 26.84
Weighted average grant-date fair value, granted (in dollars per share) \| $ / shares	9.28
Weighted average grant-date fair value, forfeited (in dollars per share) \| $ / shares	16.76
Weighted average grant-date fair value, ending balance (in dollars per share) \| $ / shares	$ 16.03
ROIC Awards
Nonvested Shares (in thousands)
Nonvested restricted shares, beginning balance (in shares) \| shares	100,000
Nonvested restricted shares, granted (in shares) \| shares	174,000
Nonvested restricted shares, forfeited (in shares) \| shares	(164,000)
Nonvested restricted shares, ending balance (in shares) \| shares	110,000
Weighted average grant-date fair value, beginning balance (in dollara per share) \| $ / shares	$ 24.39
Weighted average grant-date fair value, granted (in dollars per share) \| $ / shares	7.93
Weighted average grant-date fair value, forfeited (in dollars per share) \| $ / shares	14.20
Weighted average grant-date fair value, ending balance (in dollars per share) \| $ / shares	$ 13.53

Shared-Based Compensation - Schedule of Performance Based Awards Goals with Respect to TSR and ROIC (Detail)	9 Months Ended
	Sep. 30, 2019
TSR Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Threshold performance, percentage	35.00%
Target performance, percentage	50.00%
Maximum performance, percentage	75.00%
ROIC Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Threshold performance, percentage	4.70%
Target performance, percentage	5.80%
Maximum performance, percentage	7.00%

Shared-Based Compensation - Summary of Number of Awards Granted and Grand Date Fair Value (Detail) shares in Thousands	9 Months Ended
	Sep. 30, 2019 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Date Fair Value (in dollars per share)	$ 7.93
TSR Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards granted in fair values (in shares) \| shares	136
Grant Date Fair Value (in dollars per share)	$ 9.28
ROIC Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards granted in fair values (in shares) \| shares	174
Grant Date Fair Value (in dollars per share)	$ 7.93

Net Income (Loss) Per Share - Summary of Net Income (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Earnings Per Share [Abstract]
Net loss	$ (5,597)	$ (13,784)	$ (30,894)	$ (44,796)
Weighted average shares outstanding	42,038	28,688	42,013	27,784
Diluted shares outstanding (in shares)	42,038	28,688	42,013	27,784
Basic - net loss per share (in dollars per share)	$ (0.13)	$ (0.48)	$ (0.74)	$ (1.61)
Diluted - net loss per share (in dollars per share)	(0.13)	(0.48)	(0.74)	(1.61)
Cash dividends declared per share (in dollars per share)	$ 0.07	$ 0.07	$ 0.21	$ 0.21

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686

+ Details

Net Income (Loss) Per Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Stock Option Awards
Net Income Per Share [Line Items]
Anti-dilutive securities excluded from the calculation of diluted earnings per share from continuing operation	0.8	0.8	0.6	0.8

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Feb. 28, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Line of credit, fair value disclosure	$ 11,300	$ 11,300		$ 10,400
International lines of credit and other loans	9,897	9,897		$ 9,800
Change in fair value of interest rate swap, net of tax	$ 1,181	11,999
Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount			$ 700,000
Derivative, fixed interest rate			2.4575%
Change in fair value of interest rate swap, net of tax		$ (12,000)

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

Fair Value Measurements - Notional Amounts of the Interest Rate Swap (Details)	Sep. 30, 2019 USD ($)
February 12, 2019 - December 30, 2020
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative, notional amount	$ 700,000
December 31, 2020 - December 30, 2021
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative, notional amount	466,667
December 31, 2021 - October 19, 2022
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative, notional amount	$ 233,333

Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring $ in Thousands	Sep. 30, 2019 USD ($)
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liability - other current liabilities	$ 0
Derivative liability - other non-current liabilities	0
Total	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liability - other current liabilities	5,719
Derivative liability - other non-current liabilities	9,514
Total	15,233
Significant Unobservable Inputs (Level 3)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liability - other current liabilities	0
Derivative liability - other non-current liabilities	0
Total	$ 0

Prior Periods Financial Statement Revision - Schedule of Correction of Misstatements and Revision on Consolidated Statement of Operations and Comprehensive Income (Loss) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Accounting Changes and Error Corrections [Line Items]
Income Tax Expense (Benefit)	$ (1,283)	$ (5,609)	$ 1,535	$ (12,213)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$ (17,988)	$ (17,977)	$ (54,275)	$ (59,305)
Basic net loss per share:
Net loss per share (in dollars per shares)	$ (0.13)	$ (0.48)	$ (0.74)	$ (1.61)
Diluted net loss per share:
Net loss per share (in dollars per share)	$ (0.13)	$ (0.48)	$ (0.74)	$ (1.61)
Previously Reported
Accounting Changes and Error Corrections [Line Items]
Income Tax Expense (Benefit)				$ 12,732
Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest				(44,277)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent				$ (58,787)
Basic net loss per share:
Net loss per share (in dollars per shares)				$ (1.59)
Diluted net loss per share:
Net loss per share (in dollars per share)				$ (1.59)
Restatement Adjustment
Accounting Changes and Error Corrections [Line Items]
Income Tax Expense (Benefit)				$ (519)
Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest				(519)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent				$ (519)
Basic net loss per share:
Net loss per share (in dollars per shares)				$ (0.02)
Diluted net loss per share:
Net loss per share (in dollars per share)				$ (0.02)
Continuing Operations As Revised
Accounting Changes and Error Corrections [Line Items]
Income Tax Expense (Benefit)				$ 12,213
Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest				(44,796)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent				$ (59,306)
Basic net loss per share:
Net loss per share (in dollars per shares)				$ (1.61)
Diluted net loss per share:
Net loss per share (in dollars per share)				$ (1.61)

Prior Periods Financial Statement Revision - Schedule of Corrections of Misstatements and Revision on Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Dec. 31, 2017
Accounting Changes and Error Corrections [Line Items]
Income tax receivable	$ 1,610		$ 2,277
Total current assets	316,318		298,202
Total assets	1,553,745		1,502,901
Deferred tax liabilities	77,182		91,838
Liabilities	1,193,948		1,081,631
Retained deficit	(98,888)		(59,071)
Total stockholders' equity	359,797	$ 380,836	421,270	$ 640,515	$ 442,795	$ 486,104
Total liabilities and stockholders' equity	$ 1,553,745		1,502,901
Previously Reported
Accounting Changes and Error Corrections [Line Items]
Income tax receivable			946
Total current assets			296,871
Total assets			1,501,570
Deferred tax liabilities			93,482
Liabilities			1,083,275
Retained deficit			(62,046)
Total stockholders' equity			418,295
Total liabilities and stockholders' equity			1,501,570
Restatement Adjustment
Accounting Changes and Error Corrections [Line Items]
Income tax receivable			1,331
Total current assets			1,331
Total assets			1,331
Deferred tax liabilities			(1,644)
Liabilities			(1,644)
Retained deficit			2,975
Total stockholders' equity			2,975
Total liabilities and stockholders' equity			1,331
Continuing Operations As Revised
Accounting Changes and Error Corrections [Line Items]
Income tax receivable			2,277
Total current assets			298,202
Total assets			1,502,901
Deferred tax liabilities			91,838
Liabilities			1,081,631
Retained deficit			(59,071)
Total stockholders' equity			421,270
Total liabilities and stockholders' equity			$ 1,502,901

Label	Element	Value
Common Stock [Member]
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	$ (1,000)
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture	us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation	50,000